WO2012130823A1 - Concentrés en suspension - Google Patents

Concentrés en suspension Download PDF

Info

Publication number
WO2012130823A1
WO2012130823A1 PCT/EP2012/055379 EP2012055379W WO2012130823A1 WO 2012130823 A1 WO2012130823 A1 WO 2012130823A1 EP 2012055379 W EP2012055379 W EP 2012055379W WO 2012130823 A1 WO2012130823 A1 WO 2012130823A1
Authority
WO
WIPO (PCT)
Prior art keywords
suspension concentrate
phenyl
weight
component
compounds
Prior art date
Application number
PCT/EP2012/055379
Other languages
English (en)
Inventor
Christian Sowa
Marcus Annawald
Brigitte ZBORON
Jürgen Fries
Michael SIEBECKER
Beatrix SEIB
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of WO2012130823A1 publication Critical patent/WO2012130823A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels

Definitions

  • the present invention relates to aqueous suspension concentrates, in particular for triazole fungicides and the use of said suspension concentrates in agriculture.
  • the present invention relates to aqueous suspension concentrates, comprising a surface-active substance in encapsulated form in a microcapsule.
  • suspension concentrates are a common formulation variant for agrochemi- cals.
  • emulsion concentrates are easier to develop and to produce.
  • agricultural chemicals are often more effective in the control of pathogens if they are formulated as emulsion concentrates.
  • Suspension concentrates may have the disadvantage that their activity is weaker than that of sprays of corresponding emulsion concentrates diluted with water.
  • agrochemical cannot be formulated efficiently as emulsion concentrates because of different reasons, for example because the resulting formulations do not show sufficient storage stability or because the solubility of the active ingredient is too low.
  • Another problem connected with the formulation of active ingredients is that the active ingredient needs to be stable also when they are incorporated into an agricultural formulation. Some active ingredients are not stable in some media. Thus, one problem underlying the present invention was the provision of agrochemical formulations that are suitable for active ingredients that are instable in some regards.
  • WO 01/67860 relates to an agrotechnical formulation containing the following, respectively in relation to the total weight of the formulation: a) between 20 and 99.9 wt.-% of at least one cyclohexane polycarboxylic acid ester; b) between 0 and 70 wt.-% of wa- ter; c) between 0.1 and 60 wt.-% of at least one auxiliary agent and/or additive; and d) between 0 and 70 wt.-% of at least one active ingredient for treating plants.
  • WO 03/037084 A1 relates to a concentrated pesticidal solution which comprises one or more water-insoluble pesticides (usually 0.5-50% w/v) and lignin (suitably in the weight ratio of 1 : 10 to 1 :1 of lignin to pesticide) dissolved in a water miscible, poilar solvent, preferably N-methyl pyrrolidone.
  • the solutions are particularly useful in providing storage stable soluble concentrates of certain strobilurin fungicides.
  • WO 2010/064266 A1 relates to a liquid composition for the preparation of pesticide concentrates containing a water insoluble dialkylene glycol diester, an organic carbox- ylic acid and at least one surfactant.
  • This composition can be used to prepare formulations of pesticidal active ingredients with a concentration from 5 to 50%.
  • the crystallization of the active ingredient is prevented by the liquid composition, whose ingredients act not only as solvents but also as crystallization inhibitors during the application of the pesticide concentrate as a diluted aqueous spray.
  • WO 2005/036963 is directed to a suspension concentrates for agrochemical compounds, for example for some specific triazole fungicides, and their use in agriculture.
  • WO 03/099005 relates to microcapsule formulations consisting of A) a particulate disperse phase of microcapsules and B) a suspension containing inter alia at least one solid agrochemical active agent.
  • US 2003/01 19675 relates to microcapsule formulations comprising A) a particulate disperse phase of specific microcapsules wich contain as capsule filling at least one solid agrochemical active compound and B) a liquid aqueous phase with additives etc.
  • WO 2009/098232 relates to microcapsules comprising a lipophilic surfactant and an oil.
  • WO 2004/017734 relates to a microencapsulated agrochemical composition comprising an aqueous dispersion of microcapsules having material therein, wherein the material encapsulated comprises (a) an agrochemical (b) a water-soluble, bioperformance- enhancing adjuvant for said agrochemical which has little or no surfactant properties and (c) a water-immiscible solvent in which the agrochemical and the adjuvant are sol- uble.
  • the content of the microcapsules is set free when the formulation is dried.
  • suspension concentrate that is highly suitable for agrochemical compounds, in particular fungicidal compounds of the class of the triazoles.
  • the finding of the present invention is that, ultimately, it offers a very efficient method for formulating agrochemicals into suspension concentrates that have sufficient storage stability and show very good effectiveness when used as pesticides. Therefore, the present invention offers in particular advantages for agrochemicals that cannot be formulated as e.g. emulsion concentrates and/or that are not stable using common formulations.
  • the present invention provides an aqueous suspension concentrate, comprising the following components:
  • component (c) a surface-active substance.
  • the invention relates to formulations, wherein the surface-active substance of component (c) is present in a microcapsule and formulations comprising microcapsules that comprise a component (c), i.e. a surface-active substance, respectively.
  • the component (a) may be in particular a pesticidal active compound that is labile under common formulation conditions and/or that degrades when stored.
  • this pesticidal active compound is a fungicide.
  • Examples for such pesticidal, in particular fungicidal, compounds are compounds that contain an electro- philic substructure.
  • pesticidal, in particular fungicidal, compounds that can be efficiently formulated according to the present invention are fungicidal compounds of the triazole class that are effective against phytopathogenic fungi, in particular such triazoles that contain an electrophilic substructure and are, therefore often labile in conventional formulation media.
  • such triazoles carry a thio-triazolo group.
  • a further substructure that may be labile under conventional formu- lation conditions are epoxide structures.
  • component (a) is a triazole that carries an epoxide group.
  • said triazole contains a thio-triazolo group.
  • the active compound (component (a)) is present in sus- pended form, i.e. in the form of crystalline or amorphous particles (or a mixture of both) that are in a solid state at 20°C.
  • the active compound is present in crystalline form.
  • the viscosity of the active compound particles is at least 1 .000 mPas, preferably at least 5.000 mPas, more preferably at least 10.000 mPas.
  • the suspended active compound (component (a)) mostly has a particle size distribution with an x 5 o- value of 0.1 to 10 ⁇ , preferably 0.2 to 5 ⁇ , more preferably 0.5 to 2 ⁇ .
  • Particle size distributions with an x 5 o-value of 1 to 5 ⁇ , more preferably 1 to 3 ⁇ , more specifically 2 to 3 ⁇ may also be suitable according to the present invention.
  • the particle size distribution may be determined by means of laser diffraction in an aqueous suspension comprising the particles.
  • the preparation of the samples for example the dilution to the desired concentration for the measurement, is inter alia dependent on the fineness and concentration of the active compound in the suspension sample and on the instrument used (for example Malvern Mastersizer).
  • the proce- dure has to be worked out for the respective system used and is known to the skilled person in the art.
  • the size of the active compound particles i.e. the size (diameter) which is not ex- ceeded by 90% by weight of the active compound particles, is typically not more than 30 ⁇ , preferably not more than 20 ⁇ , in particular not more than 10 ⁇ , especially not more than 5 ⁇ , as determined by dynamic light scattering.
  • at least 60% by weight and in particular at least 80% by weight of the particles in the SCs according to the invention have diameters below 2 ⁇ .
  • the active component of component (a) is also defined to be in a solid state at a temperature of 20°C in order to be able to be formulated as suspension concentrate, wherein the active ingredient is not dissolved but particles thereof are finely distributed in the medium.
  • the component (a) is in a solid state at a temperature of 40°C, more particularly at a temperature of 50°C, more specifically it is in a solid state at a temperature of 60°C. Even more particularly, the component (a) is in a solid state at a temperature of 70°C, specifically at a temperature of 80°C.
  • the active compound (component (a)) has a melting- or degradation point above 20°C, in particular above 40°C, more particularly above 50°C, even more particularly above 60°C, even more particularly above 70°C and specifically above 80°C, for example from 80°C to 300°C.
  • the active ingredient (component (a)) is additionally characterized in that it has a solubility in water of not more than 10 g/l at 20°C/1013 mbar, preferably not more than 5 g/l at 20°C/1013 mbar, more preferably not more than 2 g/l at 20°C/1013 mbar, specifically not more than 1 g/l at 20°C/1013 mbar.
  • the active ingredient of component (a) has a solubility in water of not more than 0.5 g/l at 20°C/1013 mbar.
  • the active compound of component (a) is usually present in an amount of 0.1 to 70 weight%, in particular 1 to 50 weight%, more particularly 5 to 50 weight %, even more particularly 3 to 30 weight%, referring to the suspension concentrate.
  • the active compound according to component (a) is usually present in an amount of 10 to 25 weight%, referring to the suspension concentrate.
  • inventive formulation has shown to be very useful for fungicidal thio- triazole compounds of the triazole compound class that contain an epoxide group.
  • Compounds that contain labile functional groups such as an epoxide group can often not be efficiently and/or economically be formulated via prior art formulations. Such compounds are for example described in WO 96/38440, WO 2009/077471
  • the active compound of component (a) is a triazole, in particular , containing the following structural group (I):
  • R is an organic group of the remaining structure of the respective triazole fungicide (examples see below), and wherein D is defined as follows: D H or S-Y, wherein
  • Y is hydrogen, (Ci-C 8 )-alkyl, (Ci-C 8 )-haloalkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-haloalkenyl, CN or M 1 , wherein
  • M 1 is an alkali metal cation, an equivalent of an alkaline earth metal cation, an equivalent of a copper, zinc, iron or nickel cation or an ammonium cation of the formula (E) in which
  • Z 1 and Z 2 independently are hydrogen or d-Ce-alkyl
  • Z 3 and Z 4 independently are hydrogen, d-Ce-alkyl, benzyl or phenyl; where the phenyl groups are in each case unsubstituted or substituted by one, two or three groups independently selected from the group consisting of halogen and Ci-C4-alkyl.
  • D is hydrogen
  • D is S-Y.
  • Y in (I) is hydrogen, (Ci-Ce)-alkyl, (Ci-CeJ-haloalkyl, (C2- C 8 )-alkenyl, (C 2 -C 8 )-haloalkenyl or CN.
  • Y in (I) is hydrogen
  • Y in (I) is CN.
  • Y is Na, 1/2 Cu or an ammonium cation of the formula (E), wherein Z 1 and Z 2 preferably are independently selected from hydrogen and Ci-C 4 -alkyl and Z 3 and Z 4 are preferably independently selected from hydrogen, Ci-C 4 -alkyl, benzyl and phenyl; where the phenyl groups are in each case unsubstituted or substituted by one, two or three groups independently se- lected from the group consisting of halogen and Ci-C 4 -alkyl.
  • Z 1 , Z 2 , Z 3 and Z 4 are independently selected from hydrogen and Ci-C 4 -alkyl, in particular hydrogen, methyl and ethyl.
  • One particular suitable group (E) is HN(Et)3.
  • Y in (I) is (Ci-Ce)-alkyl or (C2- Ce)-alkenyl.
  • Y is d-Cs-alkyl, preferably Ci-C 4 -alkyl.
  • Y is C3-alkyl, and according to another specific embodiment, Y Cs-alkyl.
  • Particular examples of preferred Y are methyl, ethyl, iso-propyl, n-butyl and n-pentyl.
  • R in (I) has the following meaning (1 ): wherein # shall mean the point of attachment to the triazolo group (I) and A and B are defined as follows:
  • a or B are independently from one another unsubstituted phenyl or phenyl, that is substituted by one, two, three or four independently selected substituents L; wherein L is defined as follows:
  • a 1 is hydrogen, hydroxyl, Ci-Ce-alkyl, Ci-d-haloalkyl, amino, Ci-Ce-alkylamino or di-Ci-Ce-alkylamino,
  • a 2 is one of the groups mentioned for A 1 or d-d-alkenyl, C2-C8-haloalkenyl, C2-C8-alkynyl, C2-C8-haloalkynyl, d-d-alkoxy, Ci-d-haloalkoxy, d-d- alkenyloxy, C2-C8-haloalkenyloxy, C2-C8-alkynyloxy, C2-C8-haloalkynyloxy, d-d- cycloalkyl, C3-C8-halocycloalkyl, C3-C8-cycloalkoxy or C3-C8-halocycloalkoxy;
  • a 3 , A 4 independently of one another are hydrogen, Ci-d-alkyl, Ci-d-haloalkyl, C2-C8-alkenyl, C2-C8-haloalkenyl, C2-C8-alkynyl, C2-C8-haloalkynyl, d-d- cycloalkyl, C3-C8-halocycloalkyl, C3-C8-cycloalkenyl or C3-C8-halocycloalkenyl; where the aliphatic and/or alicyclic and/or aromatic groups of the radical definitions of L for their part may carry one, two, three or four identical or different groups R L :
  • R L is halogen, cyano, nitro, Ci-d-alkyl, Ci-d-haloalkyl, Ci-d-alkoxy, Ci-d- haloalkoxy, d-d-cycloalkyl, d-d-halocycloalkyl, d-d-cycloalkenyl, d-d- cycloalkoxy, d-d-halocycloalkoxy, Ci-Ce-alkylcarbonyl, d-Ce-alkylcarbonyloxy, d-Ce-alkoxycarbonyl, amino, Ci-Ce-alkylamino, di-Ci-Ce-alkylamino.
  • A is unsubstituted phenyl.
  • a and B independently stand for phenyl containing one, two, three or four independently selected substituents L.
  • A is phenyl, containing one, two, three or four, in particular one or two, independently selected substituents L, wherein L is as defined or as preferably defined herein.
  • one of the substituents is in 4-position (para) of the phenyl ring.
  • L is in each case independently selected from F, CI, Br, nitro, methyl, ethyl, iso-propyl, tert- butyl, methoxy, ethoxy, trifluoromethyl, trichloromethyl, difluoromethyl, difluorochloro- methyl, trifluoromethoxy, difluoromethoxy and trifluorochloromethyl.
  • L is in each case independently selected from F, CI and Br, in particular F and CI.
  • A is monosubstituted phenyl, containing one sub- stituent L, wherein L is as defined or as preferably defined herein. According to one aspect, said substituent is in para-position.
  • A is phenyl, containing two or three independently selected substituents L.
  • A is phenyl which is substituted by one F and contains a further substituent L, where the phenyl may additionally contain one or two substituents L selected independently of one another, wherein L is as defined or preferably defined herein.
  • A is disubstituted phenyl, containing exactly two substituents L that are independently selected from each other, wherein L is as defined or as preferably defined herein.
  • L is in each case independently selected from F, CI, Br, Ci-C4-alkyl, Ci-C4-haloalkyl and Ci-C4-alkoxy, in particular selected from F, CI, Ci-C4-alkyl, Ci-C4-haloalkyl and Ci-C4-alkoxy, in particular selected from F, CI, methyl, trifluoromethyl and methoxy.
  • the second substituent L is selected from methyl, methoxy and chloro.
  • one of the substituents is in the 4-position of the phenyl ring.
  • A is phenyl containing one F and exactly one further sub- stituent L as defined or preferably defined herein.
  • A is disubstituted phenyl which contains one F and a further substituent L selected from the group consisting of CI, C1-C4- alkyl, Ci-C4-haloalkyl and Ci-C4-alkoxy, in particular selected from the group consisting of CI, methyl, trifluoromethyl and methoxy.
  • the second substituent L is specifically selected from the group consisting of methyl, methoxy and chlorine.
  • one of the substituents is located in the 4-position of the phenyl ring.
  • A is 2,4-disubstituted phenyl.
  • A is 2,3-disubstituted phenyl. According to still another specific embodiment, A is 2,5-disubstituted phenyl. According to still another spe- cific embodiment, A is 2,6-disubstituted phenyl. According to still another specific embodiment, A is 3,4-disubstituted phenyl. According to still another specific embodiment, A is 3,5-disubstituted phenyl.
  • A is phenyl which is substituted by exactly two F.
  • A is 2,3-difluoro-substituted.
  • A is 2,4-difluoro-substituted.
  • A is 2,5-difluoro-substituted.
  • A is 2,6-difluoro- substituted.
  • A is 3,4-difluoro-substituted.
  • A is 3,5-difluoro-substituted.
  • A is trisubstituted phenyl containing exactly three independently selected substitutents L, wherein L is as defined or preferably defined herein.
  • A is phenyl which is substituted by exactly three F.
  • A is 2,3,4-trisubstituted, in particular 2,3,4- trifluoro-substituted.
  • A is 2,3,5-trisubstituted, in particular 2,3,5-trifluoro-substituted.
  • A is 2,3,6-trisubstituted, in particular 2,3,6-trifluoro-substituted.
  • A is 2,4,6- trisubstituted, in particular 2,4,6-trifluoro-substituted.
  • A is 3,4,5-trisubstituted, in particular 3,4,5-trifluoro-substituted.
  • A is 2,4,5-trisubstituted, in particular 2,4,5-trifluoro-substituted.
  • B is unsubstituted phenyl.
  • B is phenyl which contains one, two or three, preferably one or two, independently selected substituents L, wherein L is as defined or preferably defined herein.
  • B is phenyl which contains one, two or three substituents independently selected from halogen, NO2, amino, Ci-C4-alkyl, C1-C4- alkoxy, Ci-C4-haloalkyl, Ci-C4-haloalkoxy, Ci-C4-alkylamino, Ci-C4-dialkylamino, thio and Ci-C4-alkylthio.
  • B is phenyl which contains one, two, three or four substituents L, wherein L is independently selected from F, CI, Br, methyl, ethyl, iso- propyl, tert-butyl, methoxy, ethoxy, trifluoromethyl, trichloromethyl, difluoromethyl, difluorochloromethyl, trifluoromethoxy, difluoromethoxy and difluorochloromethyl.
  • L is in each case independently selected from F, CI and Br.
  • B is a phenyl ring that is monosubstituted by one substituent L, where according to a special aspect of this embodiment, L is located in the ortho-position to the point of attachment of the phenyl ring to the oxirane ring. L is as defined or preferably defined herein. According to a further specific embodiment, B is monochloro-substituted phenyl, in particular 2- chlorophenyl. According to a further embodiment, B is phenyl, which contains two or three, in particular two, independently selected substitutents L, wherein L is as defined or preferably defined herein.
  • B is a phenyl ring which contains a substituent L in the ortho-position and furthermore has one further independently selected substituent L.
  • the phenyl ring is 2,3-disubstituted.
  • the phenyl ring is 2,4-disubstituted.
  • the phenyl ring is 2,5-disubstituted.
  • the phenyl ring is 2,6-disubstituted.
  • B is a phenyl ring which contains a substituent L in the ortho-position and furthermore contains two further independently selected substituents L.
  • the phenyl ring is 2,3,5-trisubstituted.
  • the phenyl ring is 2,3,4-trisubstituted.
  • the phenyl ring is 2,4,5-trisubstituted.
  • L independently has the following preferred meanings:
  • L is independently selected from the group consisting of halogen, amino, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, Ci-C4-haloalkoxy, Ci-C4-alkylamino, di-Ci- C4-alkylamino, thio and Ci-C4-alkylthio, more specifically L is independently selected from the group consisting of halogen, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, C1-C4- haloalkoxy and Ci-C4-haloalkylthio, in particular halogen, Ci-C4-alkyl and Ci-C4-halo- alkyl.
  • L is independently selected from the group consisting of F, CI, Br, CH 3 , C 2 H 5 , i-C 3 H 7 , t-C 4 H 9 , OCH 3 , OC2H5, CF 3 , CCI 3 , CH F2, CCIF2, OCF 3 , OCH F2 and SCF 3 , in particular selected from the group consisting of F, CI, CH 3 , C2H5, OCH 3 , OC2H5, CF 3 , CHF 2 , OCF 3 , OCHF 2 and SCF 3 .
  • L is independently selected from the group consisting of F, CI, CH 3 , OCH 3 , CF 3 , OCF 3 and OCHF 2 . It may be preferred for L to be independently F or CI.
  • a and B are as defined as follows:
  • a phenyl which is unsubstituted or substituted by one, two or three substituents L that may be the same or different, independently selected from F, CI, Br, methyl, ethyl, tert-butyl, methoxy, ethoxy, trifluoromethyl, trichloromethyl, difluoromethyl, difluoro- chloromethyl, trifluoromethoxy, difluoromethoxy and trifluoromethylthio; and
  • B phenyl that is substituted by one, two or three substituents L that may be the same or different, independently selected from F, CI, Br, methyl, ethyl, iso-propyl, tert- butyl, methoxy, ethoxy, trifluoromethyl, trichloromethyl, difluoromethyl, difluorochloro- methyl, trifluoromethoxy, difluoromethoxy and trifluoromethylthio.
  • a and B are defined as follows: A is phenyl, 4-chlorophenyl, 2,4-chlorophenyl, 2-chlorophenyl, 2-fluorophenyl, 4- fluorophenyl, 4-methylphenyl, 3-bromo-4-fluorophenyl, 4-bromophenyl, 3,4- dichlorophenyl, 4-tert-butyl-phenyl, 3-chlorophenyl, 3,5-dichlorophenyl or 4- trifluoromethoxypghenyl and B is 2-chlorophenyl.
  • A is 4- flourphenyl and B is 2-chlorophenyl.
  • A is 4-fluorophenyl and B is 2-difluoromethoxyphenyl.
  • A is phenyl, 4-chlorophenyl, 2,4-chlorophenyl, 2-chlorophenyl, 2-fluorophenyl, 4- methylphenyl, 4-fluorophenyl, 3-bromo-4-fluorophenyl, 4-bromophenyl, 3,4- dichlorophenyl, 4-tert-butyl-phenyl, 3-chlorophenyl, 3,5-dichlorophenyl or 4- trifluoromethoxyphenyl, and B is 2-fluorophenyl.
  • A is phenyl, 4-chlorophenyl, 2,4-chlorophenyl, 2-chlorophenyl, 2-fluorophenyl, 4- methylphenyl, 4-fluorophenyl, 3-bromo-4-fluorophenyl, 4-bromophenyl, 3,4- dichlorophenyl, 4-tert-butyl-phenyl, 3-chlorophenyl, 3,5-dichlorophenyl or 4- trifluoromethoxyphenyl, and B is 2-bromophenyl.
  • a and B are defined as follows: A is 2,4-difluorophenyl and B is 2-chlorophenyl.
  • A is 3,4-difluorophenyl and B is 2-chlorophenyl.
  • A is 2,4-difluorophenyl and B is 2-fluorophenyl.
  • A is 3,4-difluorophenyl and B is 2-fluorophenyl.
  • A is 2,4-difluorophenyl and B is 2-trifluoromethylphenyl.
  • A is 3,4-difluorophenyl and B is 2-trifluoromethylphenyl.
  • A is 3,4-difluorophenyl and B is 2-methylphenyl
  • a and B are defined as follows:
  • A is phenyl and B is 2,4-dichlorophenyl.
  • A is phenyl and B is 2-fluoro-3-chlorophenyl.
  • A is phenyl and B is 2,3,4-trichlorophenyl.
  • A is 4-fluorophenyl and B is 2,4-dichlorophenyl.
  • A is 4-fluorophenyl and B is 2-fluoro-3-chlorophenyl.
  • A is 4-fluorophenyl and B is 2,3,4-trichlorophenyl.
  • A is 2-chlorophenyl and B is 2,4-dichlorophenyl.
  • A is 2-chlorophenyl and B is 2-fluoro-3-chlorophenyl.
  • A is 2-chlorophenyl and B is 2,3,4-trichlorophenyl.
  • the compounds (l)-(1 ), wherein D is SH can be synthesized from the respective compounds (l)-(1 ), wherein D is H (also called compounds (IV)-(1 )) according to processes known in the art (see patent applications cited above).
  • Compounds (l)-(1 ), wherein D is not SH and not H can in turn be synthesized from the respective compounds (l)-(1 ), wherein D is SH by derivatization (see patent applications cited above).
  • a compound (l)-(1 ) is reacted with the corresponding alkyl halide (see also WO 96/38440).
  • Z is a leaving group, such as, for example, halogen (for example CI or Br) or OS0 2 R', where R' is Ci-Ce-alkyI, Ci-Ce-haloalkyI, aryl or substituted aryl; OSO2R' is in particular a mesylate, triflate, phenyl or toluenesulfonate group.
  • a base such as, for example, sodium hydride, for example in DMF. See also, for example, EP 0 421 125 A2.
  • the double bond can be present either in the (E) or in the (Z) configuration. This is indicated by the zig-zag bond between B and the double bond.
  • the acrolein compounds can be synthesized, for example, analogously to the procedure described in DE3601927. According to one alternative, they can be prepared via an aldol synthesis according to the scheme below:
  • the double bond may be present either in (E) or in (Z) configuration. This is indicated by the zigzag bond between B and the double bond.
  • the pure enantiomers or a mixture of enantiomers (racemic or enantiomerically enriched) of the compounds (l)-(1 ) can be used in the formulation.
  • a racemic mixture is used.
  • Stereoisomers of compound (l)-(1 )-a) Formula (l)-(1 ), wherein A is 4-fluoro-phenyl and B is 2-chlorophenyl; D is SH:
  • Stereoisomers of compound (l)-(1 )-b) Formula (l)-(1 ), wherein A is 2,4-difluoro- phenyl and B is 2-chlorophenyl; D is SH:
  • Stereoisomers of compound (l)-(1 )-f) Formula (l)-(1 ), wherein A is 2,4-difluoro-phenyl and B is 2-chlorophenyl; D is H:
  • Compound (l)-(1 ) is preferably present as enantiomer mixture of the "trans” isomers, i.e. those compounds (l)-(1 ), wherein the phenyl rings are "trans” to each other, and the compounds may in each case be present in their tautomeric form or as tautomeric mixture. In particular, a racemic mixture is present. Furthermore, any other proportions of the trans-enantiomers may be present and also any one of the trans-enantiomers may also be present in pure form. On the other hand, also the "cis" isomers may be present.
  • a and B are as defined and preferably defined as for compounds (l)-(1 ), in particular A is 4-F-phenyl and B is 2-CI-phenyl or A is 2,4-F2-phenyl and B is 2-CI- phenyl, as given above.
  • the respective (IA) is formed preferably to equal or less than 10%, more preferably equal or less than 8%, even more preferably equal or less than 5%, even more preferably equal or less than 3%.
  • said product I A is formed equal or less than 0,1 %, preferably less than 0,1 %.
  • said contents are determined after 2 weeks storage at 54 °C, more specifically after 8 weeks at 40°C.
  • a and B are as defined and preferably defined as for compounds (l)-(1 ), in particular A is 4-F-phenyl and B is 2-CI-phenyl or A is 2,4-F2-phenyl and B is 2-CI- phenyl, as given above.
  • the respective (I A) is formed preferably to equal or less than 10%, more preferably equal or less than 8%, even more preferably equal or less than 5%, even more preferably equal or less than 3%.
  • said product I A is formed equal or less than 0,1 %, preferably less than 0,1 %.
  • said contents are determined after 2 weeks storage at 54 °C or 8 weeks at 40°C.
  • the organic group R in the compounds (I) and the precursors thereof carries a free hydroxy group and compounds (I) are from the triazole class of fungicides.
  • R stands for a group of formula (2):
  • R 11 and R 22 have the following meanings:
  • R 11 , R 22 independently of one another Ci-C6-alkyl, Ci-C6-haloalkyl, C3-C6-cycloalkyl,
  • R 11 and R 22 together with the carbon atom to which they are attached, form a five- or six-membered saturated or partially unsaturated ring, that can be unsubstituted or substituted by one, two, three, four or five substituents L', wherein L' stands for L as defi
  • R 33 and R 44 independently are selected from the group of hydrogen and the meaning for L as defined above.
  • R 11 and R 12 are preferably independently selected from Ci-C4-alkyl and phenyl, wherein the alkyl and phenyl group independently may contain one, two, three or four substitutents, independently selected from F, CI, Br, methoxy, ethoxy, propoxy, isopropoxy, Ci-C2-alkoximino, cyclopropyl, cyclobutyl, cyclopentyl and/or cyclohexyl.
  • R 11 stands for Ci-C4-alkyl that is substituted by one or two substituents independently selected from F, CI, methoxy, cyclopropyl, cyclopentyl and/or cyclohexyl and R 12 stands for phenyl, that is substituted by one, two, three or four substituents independently selected from F, CI, Br and methoxy.
  • R 11 is 1 -ethyl that is 1 -substituted by cyclopropyl and R 12 is 4- chlorophenyl.
  • R 11 is n-butyl and R 12 is 2,4- dichlorophenyl.
  • R 11 and R 12 are preferably independently selected from Ci-C4-alkyl, phenyl-Ci-C4-alkyl and CrCe-cycloalkyl, preferably phenyl-Ci-C4-alkyl and CrCe-cycloalkyl, wherein the alkyl, phenyl and cycloalkyl groups independently may contain one, two, three or four substitutents, independently selected from F, CI, Br, CN, methyl, ethyl, propyl, isopropyl and/or tert-butyl.
  • R 11 stands for phenyl- Ci-C4-alkyl that is substituted in the phenyl moiety by one, two, three or four substituents independently selected from F, CI and methoxy and R 12 stands for C3-C6- cycloalkyl, that is substituted by one, two, three or four substituents independently selected from F, CI, Br and methoxy.
  • R 11 is 2- chlorophenylmethyl and R 12 is 1 -chlorocyclopropyl.
  • R 11 and R 12 are preferably independently selected from Ci-C4-alkyl and phenyl-Ci-C4-alkyl, wherein the alkyl and phenyl groups may contain one, two, three or four substitutents, independently selected from F, CI, Br, CN, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, methylthio, trifluoro- methyl, trifluoromethoxy, trifluoromethylthio, chlorodifluoromethoxy, difluoromethoxy, chlorodifluoromethylthio, methoxycarbonyl, ethoxyvarbonyl, methoxyiminomethyl, 1 - methoximinoethyl and nitro.
  • R 11 stands for Ci-C4-alkyl that may be substituted by one or two substituents, independently selected from methyl, ethyl, propyl, isopropyl and tert-butyl and R 12 stands for phenyl-Ci-C4-alkyl, that is substituted in the phenyl moiety by one, two, three or four substituents independently selected from F, CI, Br, CN, methyl, trifluoromethyl and methoxy.
  • R 11 is tert- butyl and R 12 is 2-(4-chlorophenyl)-1 -ethyl.
  • R 11 and R 12 are preferably independently se- lected from phenyl, wherein the phenyl moieties may may contain one, two, three or four substitutents, independently selected from F, CI, Br, CN, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, methylthio, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, chlorodifluoromethoxy, difluoromethoxy, chlorodifluoromethylthio, methoxycarbonyl, ethoxyvarbonyl, methoxyiminomethyl, 1 -methoximinoethyl and nitro.
  • the phenyl moieties may contain one, two, three or four substitutents, independently selected from F, CI, Br, CN, methyl, ethyl, propyl, isopropyl, tert-butyl, meth
  • R 11 and R 12 independently stand for phenyl, that may contain one, two or three substitutents, independently selected from F, CI and Br.
  • R 11 is 2-fluorophenyl and R 12 is 4-fluorophenyl.
  • R 11 and R 22 together with the carbon atom to which they are attached, form a five- or six-membered saturated ring, that can be unsubstituted or substituted by one, bstituents L', wherein L' stands for L as defined above or stands for a g wherein R 33 and R 44 independently are selected from the group of hydrogen, Ci-C4-alkyl and phenyl, wherein the alkyl and phenyl groups may contain one, two, three or four substitutents, independently selected from F, CI, Br, CN, methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, methylthio, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, chlorodifluoromethoxy, difluoromethoxy and nitro.
  • L' stands for L as defined above or stands for a g
  • R 33 and R 44 independently are selected from the
  • R 11 and R 22 together with the carbon atom to which they are attached, form a five-membered saturated ring, that is substituted bstituents L', wherein L' stands for Ci-C4-alkyl or for a group and R 44 independently are selected from the group of hydrogen, Ci-C4-alkyl and phenyl, wherein the alkyl and phenyl groups may contain one, two, three or four substitutents, independently selected from F, CI, CN, methyl, isopropyl, tert-butyl and methoxy.
  • R 11 and R 22 together with the carbon atom to which they are attached, form a five-membered satu ring, that is substituted in 5-position by two methyl groups and contains a group
  • R 33 is hydrogen and R 44 is 4-chlorophenyl in 2-position.
  • R 11 and R 22 together with the carbon atom to which they are attached, form a five- or six-membered saturated ring, that can be un- substituted or substituted by one, two or three substituents, independently selected from F, CI, Br, CN , methyl, ethyl, propyl, isopropyl, tert-butyl, methoxy, ethoxy, methyl- thio, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, chlorodifluoromethoxy, di- fluoromethoxy, nitro, benzyl, wherein the phenyl moiety itself may contain on, two, three or four substituents, independently selected from F, CI, CN, methyl, isopropyl, tert-butyl and methoxy.
  • R 11 and R 22 together with the carbon atom to which they are attached, form a five-membered saturated ring, that is substituted in 5-position by two methyl groups and contains a 4-chlorobenzyl group in 2- position.
  • compounds (l)-(2) and the synthesis of precursors thereof see also WO 96/16048, WO 96/38423, EP378953, EP655443, DE 4030039, DE 3337937, DE3315681 , US4414210.
  • R stands for a group of formula (3):
  • R 55 , R 66 and R 77 have the following meanings
  • R 55 phenyl-d-Ce-alkyl, phenyl or a five- or six-membered saturated, partially unsaturated or aromatic heterocycle which contains one, two, three or four
  • R 66 , R 77 independently of one another hydrogen, Ci-C6-alkyl, Ci-C6-haloalkyl, C 3 -C6- cycloalkyl, C 3 -C6-halocycloalkyl or phenyl, wherein the alkyl, cycloalkyl or phenyl moieties may be unsubstituted or substituted by one, two or three substituents selceted from halogen, cyano, nitro, Ci-Ce-alkyl, Ci-Ce- haloalkyl, d-Ce-alkoxy, Ci-Ce-haloalkoxy
  • R 55 is phenyl, that is unsubstituted or substituted by one, two, three or four substituents independently selected from halogen, Ci-C6-alkyl, Ci-C6-haloalkyl, phenoxy-Ci-C6-alkyl and halophenyloxy, and R 66 and R 77 are independently selected from hydrogen, methyl, ethyl, n-propyl and n-butyl.
  • R 55 is phenyl, that contains one, two or three substituents independently selected from F, CI and halophenoxy, wherein the phenoxy moiety contains one or two halogen atoms selected from CI and F; and R 66 is hydrogen and R 77 is Ci-C4-alkyl.
  • R 55 is 4-(4-chlorophenoxy)-2-chlorophenyl, R 66 is hydrogen and R 77 is methyl.
  • R 55 is 2,4-dichlorophenyl, R 66 is hydrogen and R 77 is n-propyl.
  • compounds (l)-(3) and the synthesis of precursors thereof see also WO 96/41804 and Pestic. Sci, 1980, 1 1 , 95 and Research Disclosure 1989, 297,13.
  • R stands for a group of formula (4):
  • R 222 , R 333 and R 444 have the following meanings:
  • R 222 and R 333 are independently selected from hydrogen, cyano, Ci-C6-alkyl and C1-C6- haloalkyl, wherein the alkyl moieties may be unsubstituted or substituted by one, two, three or four substituents L as defined or preferably defined above for compounds, wherein R is a group (1 ).
  • R 222 and R 333 are independently selected from hydrogen, cyano and Ci-C4-alkyl, wherein the alkyl moiety may contain one, two, three or four substituents independently selected from F, CI, CN, Ci-C4-alkoxy and C1-C4- haloalkoxy.
  • q is one, two three or five, preferably one or two, and R 444 are
  • R is independently selected from L as defined or preferably defined above for compounds, wherein R is a group (1 ), in particular independently selected from F, CI, CN, methyl, isopropyl, tert-butyl and methoxy, more specifically independently selecetd from CI and F.
  • R 222 is hydrogen
  • R 333 is methyl, substituted by 1 ,1 ,2,2-tetrafluoroethoxy
  • R 444 is 2,4-dichlorophenyl.
  • R 222 is cyano
  • R 333 is n-butyl and R 444 is 4-chlorophenyl.
  • R 222 is hydrogen
  • R 333 is n-propyl
  • R 444 is 2,4-dichlorophenyl.
  • R stands for a group of formula (5):
  • # shall mean the point of attachment to the triazolo group and Q 1 , Q 2 , R 555 , R 666 , R 777 and R 888 are as defined as follows:
  • R z halogen, d-Ce-alkyl, Ci-Ce-haloalkyl, C2-C8-alkenyl, C2-Ce-halo- alkenyl, d-Ce-alkoxy, Ci-Ce-haloalkoxy, Ci-Ce-alkylcarbonyloxy, C2-C8- alkenyloxy, C2-C8-haloalkenyloxy, Ca-Ce-cycloalkyl, C3-Ce-halo
  • L 1 halogen, d-Ce-alkyl, Ci-Ce-haloalkyl, d-Ce-alkenyl, d-Ce-halo- alkenyl, C4-Cio-alkadienyl, C4-Cio-haloalkadienyl, Ci-Ce-alkoxy, Ci- Ce-haloalkoxy, Ci-Ce-alkylcarbonyloxy, C2-C8-alkenyloxy, C2-C8-halo- alkenyloxy, Ca-Ce-cycloalkyl, Ca-Ce-halocycloalkyl, Ca-Ce-cycloalkenyl, C3-C8-halocycloalkenyl, Ca-Ce-cycloalkoxy, C3-C6-cycloalkenyloxy, Ci- C6-alkylen, the aliphatic and/or alicyclic and/or aromatic groups of the definitions of L 1 may contain one, two
  • R L1 halogen, hydroxy, cyano, nitro, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci- C4-alkoxy, Ci-C4-haloalkoxy, C3-C6-cycloalkyl, C3-C6-halocycloalkyl,
  • C3-C8-cycloalkenyl Cs-Ce-cycloalkoxy, Ca-Ce-halocycloalkoxy, C1-C6- alkylen, oxy-C2-C4-alkylen, oxy-Ci-C3-alkylenoxy, Ci-Ce-alkylcarbonyl, d-Ce-alkylcarbonyloxy, Ci-Ce-alkoxycarbonyl, amino, Ci-Ce- alkylamino, di-Ci-Ce-alkylamino;
  • R666 hydrogen, halogen, Ci-Cio-alkyl, Ci-Cio-haloalkyl, C2-Cio-alkenyl, C2-Cio-halo- alkenyl, C3-Cio-cycloalkyl, C3-Cio-halocycloalkyl;
  • R 777 hydrogen, Ci-Cio-alkyl, Ci-Cio-haloalkyl, C2-Cio-alkenyl, C2-Cio-haloalkenyl, C2- Cio-alkinyl, C3-Cio-cycloalkyl, C3-Cio-halocycloalkyl, C3-Cio-cycloalkenyl, C3-C10- halocycloalkenyl, tri-Ci-Cio-alkylsilyl;
  • R888 hydrogen, Ci-Cio-alkyl, Ci-Cio-haloalkyl, C2-Cio-alkenyl, C2-Cio-halogenalkenyl, C3-Cio-cycloalkyl;
  • R 666 , R 777 and R 888 are, if it is not indicated otherwise, independently from each other unsubstituted or substituted with one, two, three, four or five L 1 , as defined above.
  • the pure enantiomers or a mixture of enantiomers (racemic or enantiomerically enriched) of the compounds (l)-(5) can be used in the formulation.
  • the racemic mixture is used.
  • the following different stereoisomers of compounds (l)-(5), alone or in any combination, can be used in the formulation according to the present invention:
  • Essential for the suspension concentrate of the present invention is the presence of an organic or inorganic acid which has a pKa value of at least 1.2 ( ⁇ 1 .2) (component (b)). It may be preferred, if the pKa value is from 1 .2 to 7.5, preferably from 1.2 to 5.0, in particular from 1 .2 to 3.0. Furthermore, it may be preferred if the pKa value of compo- nent (b) is at least 1 .8, more particularly at least 2.2, even more specifically at least 3. It has been surprisingly found within the framework of the present invention that the presence of said acid leads to a considerable improvement of the storage stabilty of the formulation compared to corresponding formulations without this component.
  • said acid (component (b)) is an organic acid.
  • the organic acid is selected from propanoic acid, acetic acid, fumaric acid, salicylic acid, lactic acid, adipinic acid, glutaric acid, tartaric acid, L- ascorbinic acid, malonic acid, oxalic acid and citric acid.
  • said acid (component (b)) is an inorganic acid.
  • the inorganic acid is selected from phosphoric acid.
  • component (b) is selected from L-ascorbinic acid, malonic acid, oxalic acid, citric acid and phosphoric acid.
  • the acid (component (b)) is in particular present in an amount of 0.001 to 15 weight %, more specifically 0.001 to 12 weight %. It may be preferred if the amount is 0.001 to 10 weight %, in particular 0.001 to 8 weight %, more particularly 0.001 to 5 weight %, more specifically 0.001 to 4 weight %, even more specifically 0.001 to 3 weight %. It may be further preferred if the amount is 0.01 to 15 weight %, more specifically 0.01 to 12 weight %. It may be also preferred if the amount is 0.01 to 10 weight %, more particularly 0.01 to 8 weight %, specifically 0.01 to 5 weight %, more specifically 0.01 to 4 weight %, even more specifically 0.01 to 3 weight %.
  • the acid is present in an amount of 0.1 to 15 weight %, more specifically 0.1 to 12 weight %. It may be further preferred if the amount is 0.1 to 10 weight %, in particular 0.1 to 8 weight %, more particularly 0.1 to 5 weight %, specifically 0.1 to 4 weight %, even more specifically 0.1 to 3 weight %. It may also be suitable in some cases if the acid is present in an amount of 1 to 15 weight %, in particular 1 to 12 weight %. It may be further suitable if the amount is 1 to 10 weight %, in particular 1 to 8 weight %, specifically 1 to 5 weight %, more specifically 1 to 4 weight %, even more specifically 1 to 3 weight %, even more specifically 1 to 2 weight %. Furthermore, it may also be suitable if component (b) is present in an amount of 0.001 to 5 weight %.
  • inventive aqueous suspension concentrate shows a certain pH value, in particular less than 6.5, in particular pH 2 to 6, more particularly 2 to 5, even more particularly 2 to 3.
  • the suspension concentrate of the present invention contains, as component (c) a su- face-active substance.
  • component (c) a su- face-active substance.
  • the amount of the surface-active substance according to com- ponent (c) will generally be from 0.5 to 30% by weight, in particular from 0.5 to 25% by weight, more particularly from 2 to 25% by weight, even more specifcally from 4 to 25% by weight. It may be preferred if the amount of component (c) will generally be from 1 to 25% by weight and particularly preferably from 5 to 20% by weight.
  • Suitable surface-active substances are the alkali metal, alkaline earth metal and ammonium salts of aromatic sulfonic acids, for example of ligno- (Borresperse ® types, such as Borresperse® Na (sodium ligninsulfonate), Borregaard, Norway), phenol-, naphthalene- (such as condensed naphthalene sulfonic acid salts (in particular Na-salt), in particular Morwet® types, such as Morwet® D 425, Akzo Nobel, USA) and dibutylnaphthalenesulfonic acid (Nekal ® types, BASF SE, Germany), and of fatty acids, alkyl- and alkylarylsulfonates, alkyl sulfates, lauryl ether sulfates and fatty alcohol sulfates, and salts of aromatic sulfonic acids, for example of ligno- (Borresperse ® types
  • Component (c) is in particular a surfactant, wherein suitable surfactants according to the present invention are selected from anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes and protective colloids.
  • suitable anionic surfactants are alkali, alkaline earth or ammonium salts of sulfonates, sulfates, phosphates or carboxylates.
  • sulfonates are alkylarylsulfonates, diphenylsulfonates, alpha-olefin sulfonates, sulfonates of fatty acids and oils, sulfonates of ethoxylated alkylphenols, sulfonates of condensed naphthalenes, sulfonates of dodecyl- and tridecylbenzenes, sulfonates of naphthalenes and alkylnaphthalenes, sulfosuccinates or sulfosuccinamates.
  • sulfates are sulfates of fatty acids and oils, of alkoxylated, in particular ethoxylated, alkylphenols (e.g. tristyrylphenols, for example Soprophor® 4D384, Rhodia), of alcohols, of ethoxylated alcohols, or of fatty acid esters.
  • phosphates are phosphate esters.
  • carboxylates are alkyl carboxylates and carboxylated alcohol or alkylphenol ethoxylates.
  • suitable cationic surfactants are quaternary surfactants, for example quaternary ammonium compounds with one or two hydrophobic groups, or salts of long- chain primary amines.
  • Suitable nonionic surfactants are alkoxylates, N-alkylated fatty acid amides, amine oxides, esters or sugar-based surfactants.
  • alkoxylates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or fatty acid esters which have been alkoxylated.
  • Ethylene oxide and/or propylene oxide may be employed for the alkoxylation, preferably ethylene oxide.
  • N-alkylated fatty acid am- ides are fatty acid glucamides or fatty acid alkanolamides.
  • esters are fatty acid esters, glycerol esters or monoglycerides.
  • sugar-based surfactants are sorbitans, ethoxylated sorbitans, sucrose and glucose esters or alkylpolygluco- sides.
  • Suitable amphoteric surfactants are alkylbetains and imidazolines.
  • Suitable block polymers are block polymers of the A-B or A-B-A type comprising blocks of polyethylene oxide and polypropylene oxide or of the A-B-C type comprising alkanol, polyethylene oxide and polypropylene oxide (such as, for example Emulsogen 3510 (butyldiglycol polyethylene/polypropylene glycol ether), Clariant GmbH, or Atlas G 5000 (butyldiglycol polyethylene/polypropylene glycol ether), Croda).
  • Emulsogen 3510 butyldiglycol polyethylene/polypropylene glycol ether
  • Clariant GmbH or Atlas G 5000 (butyldiglycol polyethylene/polypropylene glycol ether), Croda).
  • Suitable polyelectrolytes are polyacids or polybases.
  • Examples of polyacids are alkali salts of polyacrylic acid.
  • Examples of polybases are polyvinylamines or polyethyl- eneamines
  • Suitable surfactants are also protective colloids.
  • Protective colloids are typically water soluble, amphiphilic polymers. Examples include proteins und denatured proteins such as casein, polysaccharides such as water soluble starch derivatives and cellulose de- rivatives, in particular hydrophobic modified starches and celluloses, furthermore poly- carboxylates such as polyacrylic acid (polyacrylates), acrylic acid or methacrylic acid copolymers (such as for example acrylic graft copolymers such as Tersperse 2500, Huntsman) or maleic acid copolymers such as acrylic acid/olefin copolymers, acrylic acid, styrene copolymers, maleic anhydride/olefin copolymers (for example Sokalan ® CP9, BASF SE) and the esterification products of said copolymers with polyethylene glycols, polyvinylalcohol, polyvinylpyrrolidone, vinylpyrrolidone copolymers, polyvin
  • suface-active compounds as component (c) are nonionic surfactants, in particular alkanol alkoxylates and ethylene oxide/propylene oxide block polymers, in par- ticular alkanol alkoxylates. Furthermore, mixtures of the abovementioned lipophilic surfactants are preferred.
  • Preferred alkanol alkoxylates are those of the formula (A)
  • R x is straight-chain or branched alkyl or alkylene with from 4 to 32, preferably from
  • AO is an ethylene oxide radical, propylene oxide radical, butylene oxide radical, pen- tylene oxide radical, styrene oxide radical or mixtures of the abovementioned radicals in random or block sequence,
  • n 1 to 30 and
  • R 1x is hydrogen or alkyl with from 1 to 4 carbon atoms.
  • alkanol alkoxylates are those of the formula (B)
  • R xx is straight-chain or branched alkyl or alkylene with from 4 to 32, preferably from 10 to 22, particularly preferably from 6 to 18, carbon atoms,
  • PO is -CH 2 -CH(CH 3 )-0- or -(CH 2 ) 3 -0-,
  • p is numbers from 0 to 20, preferably from 3 to 10, in particular from 4 to 8
  • q is numbers from 1 to 25, preferably from 4 to 15, and
  • R 1xx is hydrogen or alkyl with from 1 to 4 carbon atoms
  • R xx is straight-chain or branched alkyl or alkylene with from 4 to 32, preferably from 6 to 22, particularly preferably from 10 to 18, carbon atoms,
  • q is numbers from 1 to 25, preferably from 3 to 15,
  • R xxx is straight-chain or branched alkyl or alkylene with from 4 to 32, preferably from 7 to 18, carbon atoms,
  • BO is -C4H8O-, which can be linear or branched
  • p is numbers from 1 to 25, preferably from 3 to 12, in particular from 4 to 7
  • q is numbers from 1 to 25, preferably from 1 to 15, in particular from 1 to 7
  • R 1xxx is hydrogen or alkyl with from 1 to 4 carbon atoms
  • RXXXX j S straight-chain or branched alkyl or alkylene with from 4 to 32, preferably from
  • p is numbers from 1 to 10, preferably from 1 to 3,
  • Rixxxx j S hydrogen or alkyl with from 1 to 4 carbon atoms.
  • suitable surface-active compounds as component (c) are Plu- rafac® LF 1300, Lutensol® 7015, Lutensol® TO 15 (isotridencanol polyethyleneglycole ether), Plurafac® LF 500 and/or Plurafac® LF 300 (BASF SE).
  • suitable surface-active compounds as component (c) are Pluronic® PE 10500 (BASF SE), Emulsogen® 1816 (Clariant) Emulsogen® 3510 (Clariant), Pluriol WSB 125 (BASF SE) and/or Wettol D1 (BASF SE).
  • suitable surface-active compounds as component (c) are fatty alcohol alkoxylates such as Plurafac® LF 120 (BASF SE), Plurafac® LF221 (BASF SE) and/or Lutensol® ON 30 (BASF SE).
  • fatty alcohol alkoxylates such as Plurafac® LF 120 (BASF SE), Plurafac® LF221 (BASF SE) and/or Lutensol® ON 30 (BASF SE).
  • suitable surface active compounds as component (c) are polyhydroxy stearic acid esters with polyethylenglycols like Tersperse® 2510 (Huntsman) or Atlox® 4912 (Croda).
  • the inventive suspension concentrate is an aqueous suspension concentrates, com- prisning water (herein also referred to as component (d)).
  • Water is preferably present in an amount of from 20 to 80% by weight, preferably 20 to 50% by weight, more preferably from 30 to 50% by weight.
  • the present invention relates to an aqueous suspension concentrate, comprising the components in the following weight %:
  • the suspension concentrate of the present invention may comprise one or more further formulation auxiliaries, wherein the choice of the auxiliary/auxiliaries usually depends on the specific use form of the suspension concentrate.
  • These further formulation auxiliaries may be present in an amount of from 0 to 80% by weight, in particular 0 to 60% by weight, more particularly from 0 to 40% by weight, even more specifically from 0 to 20% by weight. In some cases it can be preferred if such further formulation auxiliaries are present in an amount of 5 to 75% by weight, 10 to 65% by weight, 15 to 55% by weight or 20 to 45% by weight.
  • Such further formulation auxiliaries can be selected from the surface-active substances (such as dispersants, emulsifiers, surfactants, solubilizers, protective colloids, wetters and stickers) as defined or preferably defined above for component (c); solvents; solid carriers; antifoams; preservatives; antifreeze agents; organic thickeners; inorganic thickeners; bactericides; colorants; antioxidants; retention enhancers (e.g. Lutensol® ON 60); penetration enhancers; tackifiers or binders (for example for the treatment of seeds) and/or oils.
  • surface-active substances such as dispersants, emulsifiers, surfactants, solubilizers, protective colloids, wetters and stickers
  • solvents such as dispersants, emulsifiers, surfactants, solubilizers, protective colloids, wetters and stickers
  • solvents such as dispersants, emulsifiers, surfactants, solubilizers, protective colloids
  • the amount of optional further surface-active substances selected from the ones as defined or preferably defined above for component (c) may be from 0 to 20% by weight, in particular from 0.5 to 20% by weight, more particularly from 1 to 15% by weight and specifically from 5 to 15% by weight.
  • Suitable solvents are water, organic solvents such as mineral oil fractions of medium to high boiling point, such as kerosene or diesel oil, furthermore coal tar oils and oils of vegetable or animal origin, aliphatic, cyclic and aromatic hydrocarbons, e. g.
  • suitable solvents are heavy aromatic solvent mixtures such as for example Solvesso® 200 ND, Exxon mobile.
  • the solvent content in particular the content of aromatic hydrocarbons, minus any antifreeze agents, is generally in the range of from 0 to 30% by weight, in particular 0 to 20% by weight and more particularly from 0 to 15% by weight of the suspension concentrate.
  • Suitable solid carriers are, in principle, all solid substances usually used in crop protec- tion compositions, in particular in fungicides.
  • Solid carriers are, for example, mineral earths, such as silica gels, silicates, talc, kaolin, attaclay, limestone, lime, chalk, bole, loess, clay, dolomite, diatomaceous earth, calcium sulfate and magnesium sulfate, magnesium oxide, ground synthetic materials, fertilizers, such as, for example, ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas and products of vegeta- ble origin, such as cereal meal, tree bark meal, wood meal and nutshell meal, cellulose powders and other solid carriers.
  • mineral earths such as silica gels, silicates, talc, kaolin, attaclay, limestone, lime, chalk, bole, loess, clay, dolomite, diatomaceous earth, calcium sulf
  • the amount of filler is preferably chosen that the total amount of filler does not exceed 75% by weight, based on the total weight of all non- volatile components of the formulation.
  • the amount of filler may range from 0 to 50% by weight, more specifically from 1 to 50% by weight, in particular from 5 to 50% by weight, more particularly from 10 to 30 % by weight, based on the total weight of all non-volatile components of the formulation.
  • Stickers are all customary binders which can be employed in dressing products.
  • suitable binders comprise thermoplastic polymers such as polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose, furthermore polyacrylates, polyme- thacrylates, polybutenes, polyisobutenes, polystyrene, polyethylenamines,
  • polyethylenamides the aforementioned protective colloids, polyesters, polyetheresters, polyanhydrides, polyesterurethanes, polyesteramides, thermoplastic polysaccharides, e.g. cellulose derivates such as celluloseesters, celluloseethers, celluloseetheresters including methylcellulose, ethylcellullose, hydroxymethylcellulose,
  • stickers are biocompatible, i.e. they do not have a noticable phytotoxic activity.
  • the stickers are biodegradable.
  • the sticker is chosen that it acts as a matrix for the active ingredients of the formulation.
  • the amount of stickers will usually not exceed 40% by weight of the formulation and preferably ranges, if present, from 1 to 40% by weight, and in particular in the range from 1 to 30% by weight, more particularly from 1 to 20 % by weight, even more particularly from 1 to 10 % by weight, based on the total weight of the formulation.
  • Antifoams suitable for the SCs according to the invention are, for example, silicone emulsions known for this purpose (Wacker SRE-PFL, Silikon ® SRE, from Wacker SRE-PFL, Silikon ® SRE, from Wacker SRE-PFL, Silikon ® SRE, from Wacker SRE-PFL, Silikon ® SRE, from Wacker SRE-PFL, Silikon ® SRE, from Wacker
  • the amount of antifoam agent may typically be from 0.1 to 1 % by weight, in particular from 0.1 to 0.8% by weight, more particularly from 0.1 to 0.5% by weight, based on the total weight of the SC.
  • Preservatives may be added for stabilizing the suspension concentrates according to the invention.
  • Suitable preservatives are those based on isothiazolones, for example Proxel ® from ICI or Acticide ® RS from Thor Chemie GmbH or Kathon ® MK from Rohm & Haas.
  • the amount of bactericides, if present, may typically be from 0.05 to 0.5% by weight, in particular from 0.1 to 0.4 % by weight, more particularly from 0.1 to 0.2 % by weight.
  • Suitable antifreeze agents are liquid polyols, for example ethylene glycol, propylene glycol or glycerol.
  • the amount of antifreeze agents, if present, may generally be from 1 to 20% by weight, in particular from 3 to 15% by weight, in particular from 5 to 10 % by weight, based on the total weight of the suspension concentrate.
  • thickeners i. e. compounds that impart a modified flowability to composi- tions, i. e. high viscosity under static conditions and low viscosity during agitation
  • thickeners are polysaccharides and organic and anorganic clays such as Xanthan gum (Kelzan ® , CP Kelco, U.S.A.), Rhodopol ® 23 (Rhodia, France), Veegum ® (R.T. Vanderbilt, U.S.A.) or Attaclay ® (Engelhard Corp., NJ, USA).
  • the amount, if present, may typically be from 0.05 to 1 % by weight, more particularly from 0.1 to 0.8% by weight, specifically from 0.1 to- 0.5% by weight.
  • Bactericides may be added for preservation and stabilization of the composition.
  • suitable bactericides are those based on dichlorophene and benzylalcohol hemi formal (Proxel ® from ICI or Acticide ® RS from Thor Chemie GmbH and Kathon ® MK from Rohm & Haas) and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones (Acticide ® MBS from Thor Chemie GmbH (MIT/BIT (methyli- sothiazolinon/benzylisothiazolinon mixture ).
  • the amount, if present, may typically be from 0.1 to 0.5% by weight, in particular from 0.2 to 0.5% by weight, more specifically from 0.2 to 0.4% by weight.
  • Suitable colorants are pigments of low water solubility and water-soluble dyes. Examples to be mentioned und the designations rhodamin B, C. I. pigment red 1 12, C. I. solvent red 1 , pigment blue 15:4, pigment blue 15:3, pigment blue 15:2, pigment blue 15:1 , pigment blue 80, pigment yellow 1 , pigment yellow 13, pigment red 1 12, pigment red 48:2, pigment red 48:1 , pigment red 57:1 , pigment red 53:1 , pigment orange 43, pigment orange 34, pigment orange 5, pigment green 36, pigment green 7, pigment white 6, pigment brown 25, basic violet 10, basic violet 49, acid red 51 , acid red 52, acid red 14, acid blue 9, acid yellow 23, basic red 10, basic red 108.
  • the amount of colorants will usually not exceed 20% by weight of the formulation and, if present, pref- erably ranges from 0.1 to 15% by weight.
  • Antioxidants are all substances which can be used for said purpose in agrochemical compositions, for example butylated hydroxytoluene.
  • the amount, if present, may typically be from 0.1 to 2% by weight, in particular from 0.5 to 1 % by weight.
  • tackifiers or binders examples include polyvinylpyrrolidons, polyvinylacetates, polyvinyl alcohols and cellulose ethers (Tylose ® , Shin-Etsu, Japan).
  • oils Compounds which are suitable as oils are, for example, aliphatic compounds, aromatic compounds, waxes, vegetable oils, esters of vegetable oils, silicone oils, aliphatic C6-C18 alcohols, fatty acid esters with from 8 to 40 carbon atoms in the acid portion and from 1 to 20 carbon atoms in the alcohol portion, preferably ethylhexyl laurate, or dial- kyl esters of the formula (E)
  • R y and R 4y are, independently of one another, an alkyl or alkylene with from 1 to 32, preferably from 2 to 26, especially from 4 to 22, carbon atoms,
  • 0(0)R 3 (0)0 is a dicarboxyl radical in which R 3 comprises at least 3, preferably from 4 to 8, carbon atoms.
  • Preferred dialkyl esters are dibutyl succinate, dibutyl adipate and dibutyl phthalate. M ixtures of the abovementioned oils are also suitable.
  • the amount, if present, may typically be from 0.1 to 25% by weight, in particular from 1 to 20%, more specifically from 5 to 15% by weight.
  • the suspension concentrates according to the invention may also comprise other active substances, e. g. herbicides, insecticides, growth regulators, fungicides or fertilizers.
  • active substances e. g. herbicides, insecticides, growth regulators, fungicides or fertilizers.
  • strobilurins e.g. strobilurins: azoxystrobin, coumethoxy- strobin, coumoxystrobin, dimoxystrobin, enestroburin, fenaminstrobin, fenoxy- strobin/flufenoxystrobin, fluoxastrobin, kresoxim-methyl, metominostrobin, orysas- trobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, triflox- ystrobin, 2-[2-(2,5-dimethyl-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester and 2-(2-(3-(2,6-dichlorophenyl)-1 -methyl-allylideneaminooxymethyl)-phenyl)- 2-methoxyimino-N-methyl-acetamide, pyribencarb, triclopy
  • inhibitors of complex I I e. g. carboxamides: benodanil, bixafen, boscalid, carboxin, fenfuram, fluopyram, flutolanil, fluxapyroxad, furametpyr, isopyrazam, mepronil, ox- ycarboxin, penflufen, penthiopyrad, sedaxane, tecloftalam, thifluzamide, N-(4'- trifluoromethylthiobiphenyl-2-yl)-3-difluoromethyl-1 -methyl-1 H-pyrazole-4- carboxamide and N-(2-(1 ,3,3-trimethyl-butyl)-phenyl)-1 ,3-dimethyl-5-fluoro-1 H- pyrazole-4-carboxamide;
  • carboxamides benodanil, bixafen, boscalid, carboxin, fenfuram, fluopyram, fluto
  • respiration inhibitors e.g. complex I , uncouplers: diflumetorim; nitrophenyl derivates: binapacryl, dinobuton, dinocap, fluazinam; ferimzone; organometal compounds: fentin salts, such as fentin-acetate, fentin chloride or fentin hydroxide; ame- toctradin; and silthiofam;
  • SBI fungicides Sterol biosynthesis inhibitors
  • DM I fungicides triazoles: azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, diniconazole-M, ep- oxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, oxpoconazole, paclobutra- zole, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole; imidazoles: ima- zalil, pefurazoate, prochloraz, trifluoride, difenoconazole,
  • Delta14-reductase inhibitors aldimorph, dodemorph, dodemorph-acetate, fen- propimorph, tridemorph, fenpropidin, piperalin, spiroxamine;
  • - phenylamides or acyl amino acid fungicides benalaxyl, benalaxyl-M, kiralaxyl, met- alaxyl, metalaxyl-M (mefenoxam), ofurace, oxadixyl;
  • tubulin inhibitors such as benzimidazoles, thiophanates: benomyl, carbendazim, fuberidazole, thiabendazole, thiophanate-methyl; triazolopyrimidines: 5-chloro- 7-(4-methylpiperidin-1 -yl)-6-(2,4,6-trifluorophenyl)-[1 ,2,4]triazolo[1 ,5-a]pyrimidine
  • cell division inhibitors diethofencarb, ethaboxam, pencycuron, fluopicolide, zoxamide, metrafenone, pyriofenone;
  • - methionine synthesis inhibitors anilino-pyrimidines: cyprodinil, mepanipyrim, py- rimethanil;
  • blasticidin-S blasticidin-S, kasugamycin, kasugamycin hydrochloride- hydrate, mildiomycin, streptomycin, oxytetracyclin, polyoxine, validamycin A;
  • MAP / histidine kinase inhibitors fluoroimid, iprodione, procymidone, vinclozolin, fenpiclonil, fludioxonil;
  • - Phospholipid biosynthesis inhibitors edifenphos, iprobenfos, pyrazophos, iso- prothiolane;
  • Inhibitors with Multi Site Action - inorganic active substances: Bordeaux mixture, copper acetate, copper hydroxide, copper oxychloride, basic copper sulfate, sulfur;
  • organochlorine compounds e.g. phthalimides, sulfamides, chloronitriles: anilazine, chlorothalonil, captafol, captan, folpet, dichlofluanid, dichlorophen, flusulfamide, hexachlorobenzene, pentachlorphenole and its salts, phthalide, tolylfluanid, N-(4- chloro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide;
  • organochlorine compounds e.g. phthalimides, sulfamides, chloronitriles
  • guanidine dodine, dodine free base, guazatine, guazatine- acetate, iminoctadine, iminoctadine-triacetate, iminoctadine-tris(albesilate), di- thianon;
  • glucan synthesis validamycin, polyoxin B; melanin synthesis inhibitors: pyroquilon, tricyclazole, carpropamid, dicyclomet, fenoxanil;
  • Ampelomyces quisqualis e.g. AQ 10 ® from Intrachem Bio GmbH & Co. KG, Germany
  • Aspergillus flavus e.g. AFLA- GUARD ® from Syngenta, CH
  • Aureobasidium pullulans e.g. BOTECTOR ® from bio-ferm GmbH, Germany
  • Bacillus pumilus e.g. NRRL Accession No. B-30087 in SONATA ® and BALLAD ® Plus from AgraQuest Inc., USA
  • Bacillus subtilis e.g. isolate NRRL-Nr.
  • Clonostachys rosea f. catenulata also named Gliocladium catenulatum (e.g. isolate J 1446: PRESTOP ® from Verdera, Finland), Coniothyrium minitans (e.g. CONTANS ® from Prophyta, Germany), Cryphonectria parasitica (e.g. Endothia parasitica from CNICM, France), Cryptococcus albidus (e.g. YIELD PLUS ® from Anchor Bio-Technologies, South Africa), Fusarium oxysporum (e.g.
  • harzianum TH 35 e.g. ROOT PRO ® from Mycontrol Ltd., Israel
  • T. harzianum T- 39 e.g. TRICHODEX ® and TRICHODERMA 2000 ® from Mycontrol Ltd., Israel and Makhteshim Ltd., Israel
  • T. harzianum and T. viride e.g. TRICHOPEL from Agrimm Technologies Ltd, NZ
  • T. harzianum ICC012 and T. viride ICC080 e.g.
  • T. polysporum and T. harzianum e.g. BINAB ® from BINAB Bio-Innovation AB, Sweden
  • T. stromaticum e.g. TRICOVAB ® from C.E.P.L.A.C., Brazil
  • T. virens GL-21 e.g. SOILGARD ® from Certis LLC, USA
  • T. viride e.g. TRIECO ® from Ecosense Labs. (India) Pvt. Ltd., Indien, BIOCURE ® F from T. Stanes & Co. Ltd., Indien
  • T. viride TV1 e.g. T. viride TV1 from Agribiotec srl, Italy
  • Ulocladium oudemansii e.g. BOTRY-ZEN ® from Botry- Zen Ltd, NZ
  • BOTRY-ZEN e.g. BOTRY-ZEN ® from Botry- Zen Ltd, NZ
  • abscisic acid amidochlor, ancymidol, 6-benzylaminopurine, brassinolide, butralin, chlormequat (chlormequat chloride), choline chloride, cyclanilide, daminozide, dike- gulac, dimethipin, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid , maleic hydrazide, mefluidide, mepiquat (mepiquat chloride), naphthaleneacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione (prohexadione-calcium), prohydrojasmon, thidiazuron, triapenthenol, tributyl phosphorotrithioate, 2,3,5-tri-
  • acetochlor alachlor, butachlor, dimethachlor, dimethenamid, flufena- cet, mefenacet, metolachlor, metazachlor, napropamide, naproanilide, pethoxamid, pretilachlor, propachlor, thenylchlor;
  • - aryloxyphenoxypropionates clodinafop, cyhalofop-butyl, fenoxaprop, fluazifop, ha- loxyfop, metamifop, propaquizafop, quizalofop, quizalofop-P-tefuryl;
  • - (thio)carbamates asulam, butylate, carbetamide, desmedipham, dimepiperate, ep- tam (EPTC), esprocarb, molinate, orbencarb, phenmedipham, prosulfocarb, pyribu- ticarb, thiobencarb, triallate;
  • acifluorfen acifluorfen, aclonifen, bifenox, diclofop, ethoxyfen, fomesafen, lac- tofen, oxyfluorfen;
  • imidazolinones imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, ima- zethapyr;
  • - phenoxy acetic acids clomeprop, 2,4-dichlorophenoxyacetic acid (2,4-D), 2,4-DB, dichlorprop, MCPA, MCPA-thioethyl, MCPB, Mecoprop;
  • - pyridines aminopyralid, clopyralid, diflufenican, dithiopyr, fluridone, fluroxypyr, pi- cloram, picolinafen, thiazopyr;
  • - sulfonyl ureas amidosulfuron, azimsulfuron, bensulfuron, chlorimuron-ethyl, chlor- sulfuron, cinosulfuron, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flucetosulfu- ron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, meso- sulfuron, metazosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfu- ron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosulfuron, thifensul- furon, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron
  • - triazines ametryn, atrazine, cyanazine, dimethametryn, ethiozin, hexazinone, met- amitron, metribuzin, prometryn, simazine, terbuthylazine, terbutryn, triaziflam;
  • ureas chlorotoluron, daimuron, diuron, fluometuron, isoproturon, linuron, metha- benzthiazuron,tebuthiuron;
  • acetolactate synthase inhibitors bispyribac-sodium, cloransulam-methyl, di- closulam, florasulam, flucarbazone, flumetsulam, metosulam, ortho-sulfamuron, pe- noxsulam, propoxycarbazone, pyribambenz-propyl, pyribenzoxim, pyriftalid, pyrimi- nobac-methyl, pyrimisulfan, pyrithiobac, pyroxasulfone, pyroxsulam;
  • organo(thio)phosphates acephate, azamethiphos, azinphos-methyl, chlorpyrifos, chlorpyrifos-methyl, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidophos, me- thidathion, methyl-parathion, mevinphos, monocrotophos, oxydemeton-methyl, paraoxon, parathion, phenthoate, phosalone, phosmet, phosphamidon, phorate, phoxim, pirimiphos-methyl, profenofos, prothiofos, sulprophos, tetrachlorvinphos, terbufos, triazophos, trichlorfon;
  • - pyrethroids allethrin, bifenthrin, cyfluthrin, cyhalothrin, cyphenothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zeta-cypermethrin, deltamethrin, esfen- valerate, etofenprox, fenpropathrin, fenvalerate, imiprothrin, lambda-cyhalothrin, permethrin, prallethrin, pyrethrin I and II, resmethrin, silafluofen, tau-fluvalinate, te- fluthrin, tetramethrin, tralomethrin, transfluthrin, profluthrin, dimefluthrin;
  • - insect growth regulators a) chitin synthesis inhibitors: benzoylureas: chlorfluazuron, cyramazin, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, no- valuron, teflubenzuron, triflumuron; buprofezin, diofenolan, hexythiazox, etoxazole, clofentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, te- bufenozide, azadirachtin; c) juvenoids: pyriproxyfen, methoprene, fenoxycarb; d) lipid biosynthesis inhibitors: spirodiclofen, spiromesifen, spirotetramat;
  • nicotinic receptor agonists/antagonists compounds clothianidin, dinotefuran, imida- cloprid, thiamethoxam, nitenpyram, acetamiprid, thiacloprid, 1 -(2-chloro-thiazol-5- ylmethyl)-2-nitrimino-3,5-dimethyl-[1 ,3,5]triazinane;
  • GABA antagonist compounds endosulfan, ethiprole, fipronil, vaniliprole, pyraflu- prole, pyriprole, 5-amino-1 -(2,6-dichloro-4-methyl-phenyl)-4-sulfinamoyl- 1 H-pyrazole-3-carbothioic acid amide;
  • - macrocyclic lactone insecticides abamectin, emamectin, milbemectin, lepimectin, spinosad, spinetoram;
  • - mitochondrial electron transport inhibitor I acaricides: fenazaquin, pyridaben, tebufenpyrad, tolfenpyrad, flufenerim;
  • - oxidative phosphorylation inhibitors cyhexatin, diafenthiuron, fenbutatin oxide, pro- pargite;
  • cryomazine cryomazine
  • the suspension concentrates in particular the aqueous suspension concentrates, of the present invention can be prepared by suspending the active ingredient in a suitable liquid carrier, which may contain conventional formulation additives as described here- in. However, it is preferred to prepare the suspension concentrate by a shear process known in the art, i.e. by applying shear forces to a liquid which contains suspended particles of the respective active ingredient and optionally further additives.
  • the suspension concentrates of the present invention can be prepared in an agitated ball mill, wherein the active ingredient of the component (a) is comminuted with addition of the acid component (b) and the surface-active compound (c) and, if present, further formulation auxiliaries and the respective amount of water to give a fine active substance suspension. Dilution with water gives a stable suspension of the active substance at the desired active ingredient concentration.
  • the inventive formulation comprises microcapsules with sustained release of the capsule content.
  • the term "mi- crocapsule” refers to any type of capsule with an average particle diameter (d50 - z- average by means of light scattering) in the micrometer range, in particular of 1 to 20 ⁇ , preferably 1 to 10 ⁇ , even more specifically 1 to 4 ⁇ .
  • the microcapsule comprises a capsule core and a capsule wall of suitable polymers (encapsulation material), wherein the core comprises a component (c) (surface active compound as defined and preferably defined herein).
  • the encapsulation material is such that it enables sustained release of the content of the capsule.
  • the capsules suitable according to the present invention ensure that the content of the capsule is released in the amounts desired in each case, over a releatively long period of time.
  • the capsule core may be either solid or liquid.
  • the microcapsule may contain further components besides component (c), for example one or more further formulation auxiliaries, such as, for example, one or more solvents, as defined above and/or further active ingredients, wherein the microcapsules according to the invention, however, do not contain the active compound according to component (a).
  • component (c) for example one or more further formulation auxiliaries, such as, for example, one or more solvents, as defined above and/or further active ingredients, wherein the microcapsules according to the invention, however, do not contain the active compound according to component (a).
  • the microcapsule does not contain any active compounds.
  • the microcapsule contains, besides component (c), one or more solvents as defined herein.
  • the solvents may be selected from aromatic solvent mixtures (e.g. Solvesso® 200 ND, Exxon mobile) or non-polar aliphatic solvents, such as for example, mineral oils, white oils or process oils (e.g. Bayol 82)
  • Poly(meth)acrylate is a known encapsulation material, for example from WO
  • the poly(meth)acrylate comprises C1-C24 alkyl esters of acrylic and/or methacrylic acid, acrylic acid, methacryl- ic acid, and/or maleic acid in polymerized form. More preferably, the poly(meth)acrylate comprises methyl methacrylate and methacrylic acid.
  • the poly(meth)acrylate may also comprise in polymerized form one or more difunctional or polyfunctional monomers.
  • the poly(meth)acrylate may further comprise other monomers. Capsules with encapsulation material comprising a polyurethane or polyurea wall are well known and can be prepared by analogy to prior art.
  • Interfacial polymerization is usually performed in an aqueous water-in-oil emulsion or suspension of the core material containing dissolved therein at least one part of the polymer wall forming material. During the polymerization, the polymer segregates from the core material to the boundary surface between the core material and water thereby forming the wall of the microcapsule. Thereby an aqueous suspension of the microcapsule material is obtained.
  • Suitable methods for interfacial polymerization processes for preparing microcapsules containing pesticide compounds have been disclosed in prior art, e.g.
  • Melamine-formaldehyde capsules may be prepared by in situ polymerization of urea and/or melamine with formaldehyde according to known procedures (e.g. WO
  • the first step is to disperse a water-immiscible liquid or solid core material in an aqueous phase that contains urea, melamine, water-soluble urea-formaldehyde condensate, or water-soluble urea-melamine condensate.
  • the aqueous phase also contains a system modifier that enhances deposition of the aminoplast capsule shell. This system modifier may be an anionic polymer or copolymer. Shell formation occurs typically once formaldehyde is added.
  • the aqueous phase acidified, e.g. to a pH 2-4.5. The system may heated to 40-100 °C, preferably to 40-60°C.
  • each complementary wall-forming component will vary with their equivalent weights. In general, approximately stoichiometric amounts are pre- ferred, while an excess of one component may also be employed, especially an excess of polyisocyanate.
  • the total amount of wall-forming components approximately corresponds to the total amount of polymeric wall-forming materials.
  • the suspension concentrate does not contain microcapsules or other capsules.
  • the suspension concentrates, in particular the aqueous suspension concentrates, of the present invention are suitable as fungicides. They are distinguished by an outstanding effectiveness against a broad spectrum of phytopathogenic fungi, including soil-borne fungi, which derive especially from the classes of the Plasmodiophoromy- cetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, As- comycetes, Basidiomycetes and Deuteromycetes (syn. Fungi imperfecti). Some are systemically effective and they can be used in crop protection as foliar fungicides, fungicides for seed dressing and soil fungicides. Moreover, they are suitable for controlling harmful fungi, which inter alia occur in wood or roots of plants.
  • the suspension concentrates, in particular the aqueous suspension concentrates, of the present invention are particularly important in the control of a multitude of phyto- pathogenic fungi on various cultivated plants, such as cereals, e. g. wheat, rye, barley, triticale, oats or rice; beet, e. g. sugar beet or fodder beet; fruits, such as pomes, stone fruits or soft fruits, e. g.
  • the suspension concentrates in particular the aqueous suspension concentrates, of the present invention are used for controlling a multitude of fungi on field crops, such as potatoes sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugar cane; fruits; vines; ornamen- tals; or vegetables, such as cucumbers, tomatoes, beans or squashes.
  • field crops such as potatoes sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugar cane; fruits; vines; ornamen- tals; or vegetables, such as cucumbers, tomatoes, beans or squashes.
  • plant propagation material is to be understood to denote all the generative parts of the plant such as seeds and vegetative plant material such as cuttings and tubers (e. g. potatoes), which can be used for the multiplication of the plant. This includes seeds, roots, fruits, tubers, bulbs, rhizomes, shoots, sprouts and other parts of plants, including seedlings and young plants, which are to be transplanted after germination or after emergence from soil. These young plants may also be protected before transplantation by a total or partial treatment by immersion or pouring.
  • treatment of plant propagation materials with the suspension concentrates, in particular the aqueous suspension concentrates, of the present invention is used for controlling a multitude of fungi on cereals, such as wheat, rye, barley and oats; rice, corn, cotton and soybeans.
  • cultiva plants is to be understood as including plants which have been modified by breeding, mutagenesis or genetic engineering including but not limiting to agricultural biotech products on the market or in development (cf.
  • Genetically modified plants are plants, which genetic material has been so modified by the use of recombinant DNA techniques that under natural circumstances cannot readily be obtained by cross breeding, mutations or natural recombination. Typically, one or more genes have been integrated into the genetic material of a genetically modified plant in order to improve certain properties of the plant.
  • Such genetic modifications also include but are not limited to targeted post-translational modification of protein(s), oligo- or polypeptides e. g. by glycosylation or polymer additions such as prenylated, acetylated or farnesylated moieties or PEG moieties.
  • auxin herbicides
  • herbicides e. bromoxynil or ioxynil herbicides as a result of conventional methods of breeding or genetic engineering. Furthermore, plants have been made resistant to multiple classes of herbicides through multiple genetic modifications, such as resistance to both glyphosate and glufosinate or to both glyphosate and a herbicide from another class such as ALS inhibitors, HPPD inhibitors, auxin herbicides, or AC- Case inhibitors. These herbicide resistance technologies are e. g. described in Pest Managem. Sci. 61 , 2005, 246; 61 , 2005, 258; 61 , 2005, 277; 61 , 2005, 269; 61 , 2005, 286; 64, 2008, 326; 64, 2008, 332; Weed Sci.
  • cultivated plants have been rendered tolerant to herbicides by conventional methods of breeding (mutagenesis), e. g. Clearfield ® summer rape (Canola, BASF SE, Germany) being tolerant to imidazolinones, e. g. imazamox, or ExpressSun ® sunflowers (DuPont, USA) being tolerant to sulfonyl ureas, e. g. tribenuron.
  • mutagenesis e. g. Clearfield ® summer rape (Canola, BASF SE, Germany) being tolerant to imidazolinones, e. g. imazamox, or ExpressSun ® sunflowers (DuPont, USA) being tolerant to sulfonyl ureas, e. g. tribenuron.
  • plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more insecticidal proteins, especially those known from the bacterial genus Bacillus, particularly from Bacillus thuringiensis, such as ⁇ - endotoxins, e. g. CrylA(b), CrylA(c), CrylF, CrylF(a2), CryllA(b), CrylllA, CrylllB(bl ) or Cry9c; vegetative insecticidal proteins (VIP), e. g. VIP1 , VIP2, VIP3 or VIP3A; insecticidal proteins of bacteria colonizing nematodes, e. g. Photorhabdus spp.
  • VIP1 , VIP2, VIP3 or VIP3A vegetative insecticidal proteins
  • toxins produced by animals such as scorpion toxins, arachnid toxins, wasp toxins, or other insect-specific neurotoxins
  • toxins produced by fungi such Streptomy- cetes toxins, plant lectins, such as pea or barley lectins; agglutinins
  • proteinase inhibitors such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors
  • ribosome-inactivating proteins (RIP) such as ricin, maize-RIP, abrin, luffin, saporin or bryodin
  • steroid metabolism enzymes such as 3-hydroxysteroid oxidase, ecdysteroid-IDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors or HMG-CoA-reductase
  • ion channel blockers such as blockers of sodium
  • these insecticidal proteins or toxins are to be understood expressly also as pre-toxins, hybrid proteins, truncated or otherwise modified proteins.
  • Hybrid proteins are characterized by a new combination of protein domains, (see, e. g. WO 02/015701 ).
  • Further examples of such toxins or genetically modified plants capable of synthesizing such toxins are disclosed, e. g., in EP-A 374 753, WO 93/007278, WO 95/34656, EP-A 427 529, EP-A 451 878, WO 03/18810 und WO 03/52073.
  • the methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g.
  • The- se insecticidal proteins contained in the genetically modified plants impart to the plants producing these proteins tolerance to harmful pests from all taxonomic groups of athropods, especially to beetles (Coeloptera), two-winged insects (Diptera), and moths (Lepidoptera) and to nematodes (Nematoda).
  • Genetically modified plants capable to synthesize one or more insecticidal proteins are, e.
  • WO 03/018810 MON 863 from Monsanto Europe S.A., Belgium (corn cultivars producing the Cry3Bb1 toxin), IPC 531 from Monsanto Europe S.A., Belgium (cotton cultivars producing a modified version of the Cryl Ac toxin) and 1507 from Pioneer Overseas Corporation, Belgium (corn cultivars producing the Cry1 F toxin and PAT enzyme).
  • plants are also covered that are by the use of recombinant DNA techniques capable to synthesize one or more proteins to increase the resistance or tolerance of those plants to bacterial, viral or fungal pathogens.
  • proteins are the so-called “pathogenesis-related proteins” (PR proteins, see, e. g.
  • EP-A 392 225 plant disease resistance genes (e. g. potato cultivars, which express resistance genes acting against Phytophthora infestans derived from the mexican wild potato Solanum bulbocastanum) or T4-lysozym (e. g. potato cultivars capable of synthesizing these proteins with increased resistance against bacteria such as Erwinia amylvora).
  • plant disease resistance genes e. g. potato cultivars, which express resistance genes acting against Phytophthora infestans derived from the mexican wild potato Solanum bulbocastanum
  • T4-lysozym e. g. potato cultivars capable of synthesizing these proteins with increased resistance against bacteria such as Erwinia amylvora.
  • the methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above.
  • plants are also covered that are by the use of recombinant DNA tech- niques capable to synthesize one or more proteins to increase the productivity (e. g. bio mass production, grain yield, starch content, oil content or protein content), tolerance to drought, salinity or other growth-limiting environmental factors or tolerance to pests and fungal, bacterial or viral pathogens of those plants.
  • productivity e. g. bio mass production, grain yield, starch content, oil content or protein content
  • plants are also covered that contain by the use of recombinant DNA techniques a modified amount of substances of content or new substances of content, specifically to improve human or animal nutrition, e. g. oil crops that produce health- promoting long-chain omega-3 fatty acids or unsaturated omega-9 fatty acids (e. g. Nexera ® rape, DOW Agro Sciences, Canada).
  • plants are also covered that contain by the use of recombinant DNA techniques a modified amount of substances of content or new substances of content, specifically to improve raw material production, e. g. potatoes that produce increased amounts of amylopectin (e. g. Amflora ® potato, BASF SE, Germany).
  • a modified amount of substances of content or new substances of content specifically to improve raw material production, e. g. potatoes that produce increased amounts of amylopectin (e. g. Amflora ® potato, BASF SE, Germany).
  • suspension concentrates in particular the aqueous suspension concentrates, of the present invention are particularly suitable for controlling the following plant diseases:
  • Albugo spp. (white rust) on ornamentals, vegetables (e. g. A. Candida) and sunflowers (e. g. A. tragopogonis); Alternaria spp. (Alternaria leaf spot) on vegetables, rape (A. brassicola or brassicae), sugar beets (A. tenuis), fruits, rice, soybeans, potatoes (e. g. A. solani or A. alternata), tomatoes (e. g. A. solani or A. alternata) and wheat; Aphano- myces spp. on sugar beets and vegetables; Ascochyta spp. on cereals and vegetables, e. g. A. tritici (anthracnose) on wheat and A.
  • Bipolaris and Drechslera spp. (teleomorph: Cochliobolus spp.), e. g. Southern leaf blight (D. maydis) or Northern leaf blight (B. zeicola) on corn, e. g. spot blotch (B. sorokiniana) on cereals and e.g. B. oryzae on rice and turfs; Blumeria (formerly Erysiphe) graminis (powdery mildew) on cereals (e. g. on wheat or barley); Botrytis cinerea (teleomorph: Botryotinia fuckeliana: grey mold) on fruits and berries (e. g.
  • strawberries strawberries
  • vegetables e. g. lettuce, carrots, celery and cabbages
  • rape flowers, vines, forestry plants and wheat
  • Bremia lactucae downy mildew
  • Ceratocystis syn. Ophiostoma
  • spp. rot or wilt
  • broad- leaved trees and evergreens e. g. C. ulmi (Dutch elm disease) on elms
  • Cercospora spp. Cercospora leaf spots
  • corn e.g. Gray leaf spot: C. zeae-maydis
  • sugar beets e. g. C.
  • Colletotrichum teleomorph: Glomerella
  • spp. anthracnose
  • cotton e. g. C. gossypii
  • corn e. g. C. graminicola: Anthracnose stalk rot
  • soft fruits e. g. C. coccodes: black dot
  • beans e. g. C. lindemuthianum
  • soybeans e. g. C. truncatum or C. gloeosporioides
  • Corticium spp. e. g. C.
  • sa- sakii sheath blight
  • Corynespora cassiicola leaf spots
  • Cycloconium spp. e. g. C. oleaginum on olive trees
  • Cylindrocarpon spp. e. g. fruit tree canker or young vine decline, teleomorph: Nectria or Neonectria spp.
  • liriodendri Neonectria liriodendri: Black Foot Disease) and ornamentals; Dematophora (teleomorph: Rosellinia) necatrix (root and stem rot) on soybeans; Diaporthe spp., e. g. D. phaseolorum (damping off) on soy- beans; Drechslera (syn. Helminthosporium, teleomorph: Pyrenophora) spp. on corn, cereals, such as barley (e. g. D. teres, net blotch) and wheat (e. g. D. D.
  • tritici-repentis tan spot), rice and turf; Esca (dieback, apoplexy) on vines, caused by Formitiporia (syn. Phellinus) punctata, F. mediterranea, Phaeomoniella chlamydospora (earlier Phaeo- acremonium chlamydosporum), Phaeoacremonium aleophilum and/or Botryosphaeria obtusa; Elsinoe spp. on pome fruits (£. pyri), soft fruits (£. veneta: anthracnose) and vines (£.
  • ampelina anthracnose
  • Entyloma oryzae leaf smut
  • Epicoccum spp. black mold
  • Erysiphe spp. potowdery mildew
  • sugar beets £. betae
  • vegetables e. g. £. pisi
  • cucurbits e. g. £. cichoracearum
  • cabbages rape (e. g. £. cruciferarum)
  • Eutypa lata Eutypa canker or dieback, anamorph: Cytosporina lata, syn.
  • Drechslera, teleomorph Cochliobolus) on corn, cereals and rice; Hemileia spp., e. g. H. vastatrix (coffee leaf rust) on coffee; Isariopsis clavispora (syn. Cladosporium vitis) on vines; Macrophomina phaseolina (syn. phaseoli) (root and stem rot) on soybeans and cotton; Microdochium (syn. Fusarium) nivale (pink snow mold) on cereals (e. g. wheat or barley); Microsphaera diffusa (powdery mildew) on soybeans; Monilinia spp., e. g. M.
  • viticola can and leaf spot
  • soybeans e. g. stem rot: P. phaseoli, teleomorph: Diaporthe phaseolorum
  • Physoderma maydis brown spots
  • Phy- tophthora spp. wilt, root, leaf, fruit and stem root
  • paprika and cucurbits e. g. P. capsici
  • soybeans e. g. P. megasperma, syn. P. sojae
  • potatoes and tomatoes e. g. P. infestans: late blight
  • broad-leaved trees e. g. P.
  • Plasmodiophora brassicae club root
  • Plasmopara spp. e. g. P. viticola (grapevine downy mildew) on vines and P. halstedii on sunflowers
  • Podosphaera spp. powdery mildew on rosaceous plants, hop, pome and soft fruits, e. g. P. leucotricha on apples
  • Polymyxa spp. e. g. on cereals, such as barley and wheat (P. graminis) and sugar beets (P.
  • Pseudocercosporella herpotrichoides eyespot, teleomorph: Tapesia yallundae
  • Pseudoperonospora downy mildew
  • Pseudopezicula tracheiphila red fire disease or ,rotbrenner', anamorph: Phialophora
  • Puccinia spp. rusts on various plants, e. g. P. triticina (brown or leaf rust), P.
  • striiformis stripe or yellow rust
  • P. hordei dwarf rust
  • P. graminis seed or black rust
  • P. recondita brown or leaf rust
  • cereals such as e. g. wheat, barley or rye
  • P. kuehnii range rust
  • Pyrenophora anamorph: Drechslera
  • tritici-repentis tan spot
  • P. teres net blotch
  • oryzae (teleomorph: Magnaporthe grisea, rice blast) on rice and P. grisea on turf and cereals; Pythium spp. (damping-off) on turf, rice, corn, wheat, cotton, rape, sunflowers, soybeans, sugar beets, vegetables and various other plants (e. g. P. ultimum or P. aphanidermatum); Ramularia spp., e. g. R. collo-cygni (Ramularia leaf spots, Physiological leaf spots) on barley and R. beticola on sugar beets; Rhizoctonia spp.
  • R. solani root and stem rot
  • S. solani silk and stem rot
  • S. solani silk and stem rot
  • S. solani silk blight
  • R. cerealis Rhizoctonia spring blight
  • Rhizopus stolonifer black mold, soft rot
  • Rhynchosporium secalis scald
  • Sarocladium oryzae and S. attenuatum sheath rot) on rice
  • Sclerotinia spp e. g.
  • R. solani root and stem rot
  • S. solani silk blight
  • R. cerealis Rhizoctonia spring blight
  • Rhizopus stolonifer black mold, soft rot
  • Rhynchosporium secalis scald
  • Sarocladium oryzae and S. attenuatum sheath rot
  • Sclerotinia spp Sclerotinia spp.
  • seed rot or white mold on vegetables and field crops, such as rape, sunflowers (e. g. S. sclerotiorum) and soybeans (e. g. S. rolfsii or S. sclerotiorum); Septoria spp. on various plants, e. g. S. glycines (brown spot) on soybeans, S. tritici (Septoria blotch) on wheat and S. (syn. Stagonospora) nodorum (Stagonospora blotch) on cereals; Uncinula (syn.
  • Erysiphe) necator prowdery mildew, anamorph: Oidium tuckeri
  • Setospaeria spp. (leaf blight) on corn (e. g. S. turcicum, syn. Helminthosporium turcicum) and turf; Sphacelotheca spp. (smut) on corn, (e. g. S. reiliana: head smut), sorghum und sugar cane; Sphaerotheca fuliginea (powdery mildew) on cucurbits; Spongospora subterra- nea (powdery scab) on potatoes and thereby transmitted viral diseases; Stagonospora spp.
  • S. nodorum Stagonospora blotch, teleomorph: Leptosphaeria [syn. Phaeosphaeria] nodorum
  • wheat Synchytrium endobioticum on potatoes (potato wart disease)
  • Taphrina spp. e. g. T. deformans (leaf curl disease) on peaches and T. pruni (plum pocket) on plums
  • Thielaviopsis spp. black root rot
  • tobacco, pome fruits, vegetables, soybeans and cotton e. g. T. basicola (syn. Chalara elegans); Tilletia spp.
  • the suspension concentrates, in particular the aqueous suspension concentrates, of the present invention are also suitable for controlling harmful fungi in the protection of stored products or harvest and in the protection of materials.
  • the term "protection of materials” is to be understood to denote the protection of technical and non-living materials, such as adhesives, glues, wood, paper and paperboard, textiles, leather, paint dispersions, plastics, colling lubricants, fiber or fabrics, against the infestation and de- struction by harmful microorganisms, such as fungi and bacteria.
  • Ascomycetes such as Ophiostoma spp., Ceratocystis spp., Aureobasidium pullulans, Sclerophoma spp., Chaetomium spp., Humicola spp., Petriella spp., Trichurus spp.; Basidiomycetes such as Coniophora spp., Coriolus spp., Gloeophyllum spp., Lentinus spp., Pleurotus spp., Poria spp., Serpula spp.
  • Tyromyces spp. Deuteromycetes such as Aspergillus spp., Cladosporium spp., Penicillium spp., Trichorma spp., Alter- naria spp., Paecilomyces spp. and Zygomycetes such as Mucor spp., and in addition in the protection of stored products and harvest the following yeast fungi are worthy of note: Candida spp. and Saccharomyces cerevisae.
  • the suspension concentrates, in particular the aqueous suspension concentrates, of the present invention may be used for improving the health of a plant.
  • the invention also relates to a method for improving plant health by treating a plant, its propagation material and/or the locus where the plant is growing or is to grow with an effective amount of a suspension concentrate, in particular the aqueous suspension concen- trates, of the present invention.
  • plant health is to be understood to denote a condition of the plant and/or its products which is determined by several indicators alone or in combination with each other such as yield (e. g. increased biomass and/or increased content of valuable ingredients), plant vigor (e. g. improved plant growth and/or greener leaves ("greening effect")), quality (e. g. improved content or composition of certain ingredients) and tolerance to abiotic and/or biotic stress.
  • yield e. g. increased biomass and/or increased content of valuable ingredients
  • plant vigor e. g. improved plant growth and/or greener leaves ("greening effect")
  • quality e. g. improved content or composition of certain ingredients
  • tolerance to abiotic and/or biotic stress e. g. improved content or composition of certain ingredients
  • inventive formulations are employed by treating the fungi or the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms to be pro- tected from fungal attack with a fungicidally effective amount of the formulations.
  • the application can be carried out both before and after the infection of the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms by the fungi.
  • Plant propagation materials may be treated with the suspension concentrates, in particular the aqueous suspension concentrates, of the present invention prophylacti- cally either at or before planting or transplanting.
  • the active compounds contained in the inventive formulations can be present in dif- ferent crystal modifications whose biological activity may differ.
  • the use of the mixture for controlling a particular phytopathogenic fungus is also meant to encompass the respective method for controlling the particular phytopathogenic fungi, wherein the fungi or the materials, plants, the soil or seed to be protected from fungal attack are treated with an effective amount of a fungicidal mixture as defined in that context.
  • the present invention relates to the use of the suspen- sion concentrates, in particular the aqueous suspension concentrates, of the present invention for the control of cereal pathogens.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or l)-(1 )-d), as defined above.
  • the suspension concentrate of the present invention is suitable for controlling wheat pathogens, particularly for controlling the wheat pathogens selected from Septoria tritici, Stagonospora nodorum, Pyrenophora tritici repentis, Puccinia recondita, Puccinia striiformis and Blumeria graminis.
  • said suspension concentrate is useful for the control of the pathogens selected from Fusarium culmorum, Fusarium graminearum and Pseudocercosporella herpotrichoides.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d
  • suspension concentrate of the present invention is suitable for controlling barley pathogens, in particular for controlling the barley pathogens, selected from Pyrenophera teres, Rhychosporium secalis, Puccinia hordei and Blumeria graminis. Furthermore, the suspension concentrate of the present invention is useful for con- trolling the barley pathogens, selected from Ramularia collo-cygni and Pseudocercosporella herpotrichoides.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (I)- (1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (I)- (1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as
  • the present invention relates to the use of the suspension concentrate of the present invention for the control of soy pathogens.
  • the suspension concentrate of the present invention is suitable for controlling soy pathogens selected from phakopsora pachyrizi, P. meibomiae and Microsphaera diffusa.
  • the suspension concentrate of the present invention may also be effect- lively used for the control of the so-called FDC (Foliar Disease Complex), e.g. against Septoria glycines, Cercospora kikuchii, C. sojina, Corynespora cassiicola and/or Alter- naria spp..
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (I)- (1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (I)- (1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as
  • the present invention relates to the use of the suspension concentrate of the present invention for the control of corn pathogens.
  • the suspension concentrate of the present invention is suitable for controlling corn pathogens selected from Cercospora zeae-maydis, Puccinia sorghi and Helmin- thosporium maydis.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (I)- (1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the present invention relates to the use of the suspension concentrate of the present invention for the control of sugar beet pathogens.
  • the suspension concentrate of the present invention is suitable for controlling corn pathogens selected from Cercospora beticola, Erysiphe betae, Ramu- laria betae and Uromyces betae.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (I)- (1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (I)- (1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as
  • the present invention relates to the use of the suspension concentrate of the present invention for the control of oil seed rape and canola pathogens, in particular selected from Sclerotinia sclerotiorum, Leptosphearia maculans and Alternaria alternate.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d
  • the present invention relates to the use of the suspension concentrate of the present invention for the control of rice pathogens, selected from Rhizoctonia solani and Pyricularia oryzae.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )- e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the suspension concentrate of the present invention is also suitable for the control of pathogens in specialty crops, such as turf, potato, tomato, cucurbits, grapes, apples, ornamentals and bananas.
  • Turf pathogens that may be controlled according to the present invention are selected from Sclerotinia homeocarpa and Rhizoctonia solani.
  • Po- tato and tomato pathogens that may be controlled according to the present invention are in particular selected from Alternaria solani, A. alternata and Rhizoctonia solani.
  • a cucurbit pathogen that may be controlled according to the present invention is in particular Sphaerotheca fuliginea.
  • a grape pathogen that may be controlled according to the present invention is in particular Uncinula necator and Botrytis cinerea.
  • An apple pathogen that may be controlled according to the present invention is in particular
  • Ornamental pathogens that may be controlled according to the present invention are in particular selected from Sphaerotheca fuliginea, Diplocarpon spp., Alternaria spp. and Sclerotinia spp.
  • Banana pathogens that may be controlled according to the present invention are in particular se- lected from Mycosphaerella fijiensis and Mycosphaerella musicola.
  • the suspension concentrate comprises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )- c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the suspension concentrates containing in addition to the active ingredient of component (a) a second or a second and a third active ingredient, according to the present invention are further described.
  • the use of the mixture for controlling a particular phy- topathogenic fungus is also meant to encompass the respective method for controlling the particular phytopathogenic fungi, wherein the fungi or the materials, plants, the soil or seed to be protected from fungal attack are treated with an effective amount of a fungicidal mixture as defined in that context.
  • the suspension concentrates of the invention comprise one active ingredient as component (a) and one further active compound, wherein said one further active compound is selected from pyraclostrobin, fluxapyroxad, fenpropi- morph, prothioconazole and chlorothalonil.
  • the weight ratio from the active compound according to component (a) and this second active ingredient is preferably 1 :20 to 20:1 , particularly preferably in the range of from 1 :10 to 10:1 , in particular in the range of from 1 :3 to 3:1 . It may also be preferable that the weight ratio is in the range of from 1 :2 to 2:1 .
  • the suspension concentrate com- prises as component (a) a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )- b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-d), as defined above.
  • the presence of the active compound of component (a) and the second active ingredi- ent, or the active compound of component (a), the second active ingredient and the third active compound (see below) as specified herein applied in the inventive suspension concentrates, may show better control of harmful fungi than with the individual compounds (synergistic effects). As mentioned above, these mixtures are of interest with a view to reducing the application rates, since many show, at a reduced total amount of active compounds applied, an improved activity against harmful fungi, in particular for certain indications.
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred if the first active ingredient according to component (a) to the second active ingredient are present 1 :1 to 2:1.
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 1 :1 to 2:1.
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 3:1 to 2:1.
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothio- conazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (I)- (1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (I)- (1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 2:1 to 1 :1 .
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 2:1 to 1 :1 .
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 2:1 to 1 :1.
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 2:1 to 1 :1.
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (I)- (1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )- d), as defined above.
  • especially preferred weight ratios of the active ingredients are 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 2:1 to 1 :1 .
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • especially preferred weight ratios of the active ingredients are 20:1 bis 1 :20, more specifically 5:1 to 1 :5, in particular 3:1 to 1 :3, more particularly 2:1 to 1 :2, wherein it may be especially preferred, if the first active ingredient according to component (a) to the second active ingredient are present 1 :1 to 1 :2.
  • the second active ingredient is fluxapyroxad.
  • the second active ingredient is pyraclostrobin.
  • the second active ingredient is fenpropimorph.
  • the second active ingredient is prothioconazole.
  • the second active ingredient is chlorothalonil.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (I)- (1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • the suspension concentrate comprises one active ingredient as component (a) and two additional active compounds.
  • the second active compound is a) fluxapyroxad or b) prothioconazole and the third active compound is, if the second active compound is fluxapyroxad, selected from a) py- raclostrobin and fenpropimorph; and, if the second active compound is prothioconazole, selected from b) fluxapyroxad, bixafen, pyraclostrobin, dimoxystrobin, picox- ystrobin, fluoxastrobin, fluopyram and penflufen.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the weight ratio of the active compound of component (a) to the second active ingredient is preferably 1 :20 to 20:1 . It may be preferable for the weight ratio to be in the region of from 1 :10 to 10:1 , preferably from 1 :3 to 3:1 , in particular from 1 :2 to 2:1 .
  • the weight ratio of the active compound of component (a) to the third active ingredinet is in the range of from 1 :20 to 20:1 . It may be preferable for the weight ratio to be in the region of from 1 :10 to 10:1 , preferably from 1 :3 to 3:1 , in particular from 1 :2 to 2:1 .
  • the weight ratio of the active compound of component (a) to the third active ingredient is in the range of from 1 :20 to 20:1 , and in particular in the range of from 1 : 10 to 10:1 . It may be preferable for the weight to be in the range of from 1 :3 to 3:1 , in particular from 1 :2 to 2:1.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (I)- (1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (l)-(1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (I)- (1 )-b), (l)-(1 )-c) or (l)-(1 )-
  • the suspension concentrate comprises as sec- ond active compound fluxapyroxad and as third active compound pyraclostrobin, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2.
  • the weight ratios for the three components are active compound of component (a) to the second active compound are 1 :1 to 2:1 ; active compound of component (a) to the third active compound 1 :1 to 2:1 and the second active compound to the third active compound 1 : 1 to 1 :2. It may be preferred if the components are present in a weight ratio of 1 :1 :1 to 2:1 :2 or 2:1 :2 to 2:1 :1 .
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (I)- (1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )- d), as defined above.
  • the suspension concentrate comprises as second active compound fluxapyroxad and as third active compound fenpropimorph, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2.
  • the weight ratios for the three components are active compound of component (a) to the second active compound are 1 :1 to 2:1 ; active compound of component (a) to the third active com- pound 1 :3 to 1 :6 and the second active compound to the third active compound 1 :3 to 1 :6. It may be preferred if the components are present in a weight ratio of 1 :1 :3 to 1 :1 :6.
  • the suspension concentrate comprises as component (a) in each case a compound (I)- (1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (I)- (1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-d), as defined above.
  • the suspension concentrate comprises as second active compound prothioconazole and as third active compound fluxapyroxad, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of 1 :1 :1 to 2:2:1 .
  • the weight ratios for the three components are active compound of component (a) to the second active compound 1 :1 to 2:1 ; active compound of component (a) to the third active compound 1 :1 to 2:1 and the second active compound to the third active compound 1 :1 to 2:1.
  • the suspension concentrate comprises as component (a) in each case a compound (I)- (1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (I)- (1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-d), as defined above.
  • the suspension concentrate comprises as second active compound prothioconazole and as third active compound bixafen, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of 1 :1 :1 to 2:2:1 .
  • the weight ra- tios for the three components are the active compound of component (a) to the second active compound 1 :1 to 2:1 ; the active compound of component (a) to the third active compound 1 :1 to 2:1 and the second active compound to the third active compound 1 :1 to 2:1 .
  • the suspension concentrate comprises as component (a) in each case a compound (I)- (1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (I)- (1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-d), as defined above.
  • the suspension concentrate comprises as sec- ond active compound prothioconazole and as third active compound penflufen, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of 1 :1 :1 to 2:2:1 .
  • the weight ratios for the three components are the active compound of component (a) to the second active compound 1 :1 to 2:1 ; the active compound of component (a) to the third active compound 1 :1 to 2:1 and the second active compound to the third active compound 1 :1 to 2:1 .
  • the suspension concentrate comprises as component (a) in each case a compound (I)- (1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • a compound (I)- (1 ) more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-d), as defined above.
  • the suspension concentrate comprises as second active compound prothioconazole and as third active compound pyraclostrobin, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of 1 :1 :1 to 1 :1 :2.
  • the weight ratios for the three components are the active compound of component (a) to the second active compound 1 :1 to 2:1 ; the active compound of component (a) to the third active compound 1 :1 to 1 :2 and the second active compound to the third active compound 1 :1 to 1 :2.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the suspension concentrate comprises as second active compound prothioconazole and as third active compound dimoxystrobin, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of 1 :1 :1 to 1 :1 :2.
  • the weight ratios for the three components are the active compound of component (a) to the second active compound 1 :1 to 2:1 ; the active compound of component (a) to the third active compound 1 :1 to 1 :2 and the second active compound to the third active compound 1 :1 to 1 :2.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the suspension concentrate comprises as second active compound prothioconazole and as third active compound picoxystrobin, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of the active compound of component (a) to the second active compound 1 :1 to 2:1 ; the active compound of component (a) to the third active compound 1 :1 to 1 :2 and the second active compound to the third active compound 1 :1 to 1 :2. Surprisingly, this mixture shows synergistical effects and the components are in particular used in synergistically effective amounts.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (I)- (1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )- d), as defined above.
  • the suspension concentrate comprises as second active compound prothioconazole and as third active compound fluoxastrobin, wherein two of the three active compounds are preferably present in a weight ratio of 20:1 to 1 :20, more specifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of the active compound of component (a) to the second active compound 1 :1 to 2:1 ; the active compound of component (a) to the third active compound 1 :1 to 1 :2 and the second active compound to the third ac- tive compound 3 1 :1 to 1 :2.
  • the suspension concentrate comprises as component (a) in each case a compound (l)-(1 ), more specifically selected from the compounds (l)-(1 )-a), (I)- (1 )-b), (l)-(1 )-c), (l)-(1 )-d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )- d), as defined above.
  • the suspension concentrate comprises as second active compound prothioconazole and as third active compound orysastrobin, wherein two of the components are present in a weight ratio of 20:1 to 1 :20, more spe- cifically 5:1 to 1 :5, in particular 2:1 to 1 :2. It may be preferred if the components are present in a weight ratio of the active compound of component (a) to the second active compound 1 :1 to 2:1 ; the active compound of component (a) to the third active compound 1 :1 to 1 :2 and the second active compound to the third active compound 1 :1 to 1 :2. Surprisingly, this mixture shows synergistical effects and the components are in particular used in synergistically effective amounts.
  • the suspension concentrate comprises as component (a) in each case a compound (I)- (1 ), more specifically selected from the compounds (l)-(1 )-a), (l)-(1 )-b), (l)-(1 )-c), (l)-(1 )- d), (l)-(1 )-e) and (l)-(1 )-f), preferably (l)-(1 )-b), (l)-(1 )-c) or (l)-(1 )-d), as defined above.
  • the suspension concentrates according to the invention are distinguished in particular by better storage stability compared to the known suspension concentrates and suspo- emulsion concentrates.
  • the suspension concentrates may be transformed into homogenous spray liquids that may be applicated as commonly known, i.e. by means of spraying, pouring or injecting.
  • the application rates may vary in wide ranges and may be varied according to the specific use, the specific active ingredients contained therein and/or the concentration of the formulation.
  • Pluronic® PE 10500 (18%): Block polymers A-B-A of polyethylene oxide and poly propylene oxide (BASF SE)
  • Wettol® D1 Phenolsulfonic acid formaldehyde polycondensate sodium salt (BASF SE)
  • Wacker SRE-PFL silicone emulsion (Wacker Chemie)
  • Xanthan Gum polysaccharide Acticide MBS MIT / BIT mixture (methylisothiazolinon / benzylisothiazo- linon mixture) (Thor Chemie GmbH)
  • Lutensol® TO 15 Isotridecanol polyethylengylcol ether (BASF SE) Solvesso® 200 ND Heavy aromatic solvent mixture (Exxon mobile) Borresperse® Na Sodium ligninsulfonate (Borregaard)
  • Emulsogen® 3510 Butyldiglycol polyethylen-/polypropylen glycol ether (Clar- iant)
  • Tersperse® 2500 Acrylic graft copolymer (Huntsman)
  • Morwet® D 425 condensated naphthalene sulfonic acid, sodium salt (Akzo
  • Soprophor® 4D384 Tristyrylphenol polyethylenglycol ether sulfate, ammonium salt (Rhodia)
  • Examples 1 to 5 - storage stability content example 1 example 2 example 3 example 4 example 5
  • example 6 example 7 example 8 example 9 example 10 compound (I)- 50 200 200 200 200 (1 )-b) [g/i]

Abstract

La présente invention concerne un concentré en suspension aqueuse, comprenant un composé actif pesticide, qui est à l'état solide à une température de 20 °C, un acide organique ou inorganique qui a une valeur pKa d'au moins 1,2 (≥ 1,2) et une substance tensioactive.
PCT/EP2012/055379 2011-03-30 2012-03-27 Concentrés en suspension WO2012130823A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160455.9 2011-03-30
EP11160455 2011-03-30

Publications (1)

Publication Number Publication Date
WO2012130823A1 true WO2012130823A1 (fr) 2012-10-04

Family

ID=44650691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/055379 WO2012130823A1 (fr) 2011-03-30 2012-03-27 Concentrés en suspension

Country Status (2)

Country Link
AR (1) AR085757A1 (fr)
WO (1) WO2012130823A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017023819A1 (fr) * 2015-07-31 2017-02-09 Summit Agro Usa, Llc Concentré en suspension
US10271547B2 (en) * 2015-02-18 2019-04-30 Melchior Material And Life Science France Particles containing pheromones and production process

Citations (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3516941A (en) 1966-07-25 1970-06-23 Minnesota Mining & Mfg Microcapsules and process of making
US3577515A (en) 1963-12-13 1971-05-04 Pennwalt Corp Encapsulation by interfacial polycondensation
US4087376A (en) 1974-07-10 1978-05-02 Ncr Corporation Capsule manufacture
US4280833A (en) 1979-03-26 1981-07-28 Monsanto Company Encapsulation by interfacial polycondensation, and aqueous herbicidal composition containing microcapsules produced thereby
US4414210A (en) 1979-10-02 1983-11-08 Rohm And Haas Company 2-Hydroxyarylethyltriazole fungicides
DE3337937A1 (de) 1982-10-28 1984-05-03 Sandoz-Patent-GmbH, 7850 Lörrach Neue azolderivate
DE3315681A1 (de) 1983-04-29 1984-10-31 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von oxiranen
DE3601927A1 (de) 1986-01-23 1987-07-30 Basf Ag Alpha, beta-substituierte acroleine, verfahren zu deren herstellung und deren verwendung
EP0374753A2 (fr) 1988-12-19 1990-06-27 American Cyanamid Company Toxines insecticides, gènes les codant, anticorps les liant, ainsi que cellules végétales et plantes transgéniques exprimant ces toxines
EP0378953A1 (fr) 1988-12-29 1990-07-25 Rhone-Poulenc Agrochimie Benzylidène azolylméthylecycloalcane et utilisation comme fongicide
EP0386557A1 (fr) 1989-03-10 1990-09-12 BASF Aktiengesellschaft Méthode pour combattre les champignons excluant le cas du traitement du corps humain ou animal.
EP0392225A2 (fr) 1989-03-24 1990-10-17 Ciba-Geigy Ag Plantes transgéniques résistantes aux maladies
EP0421125A2 (fr) 1989-09-09 1991-04-10 BASF Aktiengesellschaft Azolméthyloxirannes fongicides
EP0427529A1 (fr) 1989-11-07 1991-05-15 Pioneer Hi-Bred International, Inc. Lectines larvicides, et résistance induite des plantes aux insectes
US5049182A (en) 1989-02-03 1991-09-17 Ici Americas Inc. Single-package agricultural formulations combining immediate and time-delayed delivery
EP0451878A1 (fr) 1985-01-18 1991-10-16 Plant Genetic Systems, N.V. Modification de plantes par techniques de génie génétique pour combattre ou contrôler les insectes
EP0457154A1 (fr) 1990-05-16 1991-11-21 BASF Aktiengesellschaft Microcapsules
DE4030039A1 (de) 1990-09-22 1992-03-26 Bayer Ag Verfahren zur herstellung von 2-(1-chlor-cyclopropyl)-1- (2-chlor-phenyl)-3-(1,2,4-triazol-1-yl- propan-2-ol
WO1993007278A1 (fr) 1991-10-04 1993-04-15 Ciba-Geigy Ag Sequence d'adn synthetique ayant une action insecticide accrue dans le mais
US5229122A (en) 1986-02-07 1993-07-20 Burroughs Wellcome Co. Pesticidal compositions
US5310721A (en) 1992-01-03 1994-05-10 Ciba-Geigy Corporation Process for the preparation of microcapsules using a salt of a partial ester of a styrene-maleic anhydride copolymer
EP0619073A2 (fr) 1993-04-05 1994-10-12 Monsanto Company Formulations fluides pesticides à base d'eau
WO1995013698A1 (fr) 1993-11-15 1995-05-26 Zeneca Limited Microcapsules contenant des suspensions de composes biologiquement actifs
EP0655443A2 (fr) 1993-11-11 1995-05-31 Kureha Chemical Industry Co., Ltd. Procédé pour la préparation de dérivées à azolylméthyl cycloalcanol
WO1995034656A1 (fr) 1994-06-10 1995-12-21 Ciba-Geigy Ag Nouveaux genes du bacillus thuringiensis codant pour des toxines actives contre les lepidopteres
WO1996003040A1 (fr) 1994-07-22 1996-02-08 Ciba-Geigy Ag Procede de preparation de microparticules spheriques contenant des composes biologiquement actifs
WO1996016048A1 (fr) 1994-11-21 1996-05-30 Bayer Aktiengesellschaft Derives triazolyle microbicides
WO1996038440A1 (fr) 1995-06-01 1996-12-05 Bayer Aktiengesellschaft Triazolylmethyl-oxirannes
WO1996038423A1 (fr) 1995-06-01 1996-12-05 Bayer Aktiengesellschaft (mercapto-triazolylmethyle)-cyclopentanols utilises comme microbicides
WO1996041804A1 (fr) 1995-06-13 1996-12-27 Bayer Aktiengesellschaft (mercapto-triazolylmethyl)-dioxacycloalcanes microbicides
DE19528300A1 (de) 1995-08-02 1997-02-06 Bayer Ag 2-Phenylethyl-mercapto-triazole
DE19529089A1 (de) 1995-08-08 1997-02-13 Bayer Ag Mercapto-triazolyl-nitrile
WO1997041107A1 (fr) 1996-04-30 1997-11-06 Bayer Aktiengesellschaft Triazolyl-mercaptides et leur utilisation comme microbicides
US5705174A (en) 1995-06-07 1998-01-06 American Cyanamid Company Process for the preparation of microcapsule compositions
EP0917829A1 (fr) 1997-11-12 1999-05-26 Fabriques De Tabac Reunies S.A. Procédé d'acheminement d'un flux de tabac, distributeur et machine de fabrication de cigarettes équipée d'un tel distributeur
EP0917828A2 (fr) 1997-11-20 1999-05-26 British-American Tobacco (Germany) GmbH Procédé et dispositif de régulation de l'humidité de sortie du tabac
EP0917822A1 (fr) 1997-11-20 1999-05-26 Sumitomo Chemical Company, Limited Méthode pour la lutte contre les ectoparasites d'animaux
WO1999044331A1 (fr) 1998-02-27 1999-09-02 Intel Corporation Procede et appareil pour cacher des cles cryptographiques utilisant un codage et un calcul par synchronisation d'autocorrelation
WO2000010392A1 (fr) 1998-08-18 2000-03-02 Fmc Corporation Combinaison d'au moins deux principes actifs au moyen de formulations microencapsulees
WO2000048465A1 (fr) 1999-02-19 2000-08-24 Thies Technology Lutte contre les ravageurs
EP1109450A1 (fr) 1998-09-05 2001-06-27 Bayer Ag Formulations de microcapsules
WO2001067860A1 (fr) 2000-03-13 2001-09-20 Basf Aktiengesellschaft Formulation agrotechnique
WO2001068234A1 (fr) 2000-03-17 2001-09-20 Bayer Aktiengesellschaft Suspensions en microcapsules
WO2002015701A2 (fr) 2000-08-25 2002-02-28 Syngenta Participations Ag Nouvelles toxines insecticides derivees de proteines cristallines insecticides de $i(bacillus thuringiensis)
WO2003018810A2 (fr) 2001-08-31 2003-03-06 Syngenta Participations Ag Toxines cry3a modifiees et sequences d'acides nucleiques les codant
WO2003037084A1 (fr) 2001-10-31 2003-05-08 Syngenta Limited Formulations pesticides
WO2003052073A2 (fr) 2001-12-17 2003-06-26 Syngenta Participations Ag Nouvel evenement du mais
WO2003099005A1 (fr) 2002-05-29 2003-12-04 Bayer Cropscience Ag Formulations pour microcapsules
WO2004017734A1 (fr) 2002-08-22 2004-03-04 Syngenta Limited Composition agrochimique microencapsulee
WO2005036963A1 (fr) 2003-09-23 2005-04-28 Bayer Cropscience Aktiengesellschaft Suspensions concentrees
WO2005056548A1 (fr) 2003-12-11 2005-06-23 Cheminova A/S Epoxiconazole enantiomeriquement pur et ses utilisations en tant qu'agent phytosanitaire
WO2008071649A2 (fr) 2006-12-13 2008-06-19 Basf Se Microcapsules
DE102007055813A1 (de) 2006-12-22 2008-06-26 Basf Se Thermisch zerstörbare Mikrokapseln
WO2009077497A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, utilisation de ceux-ci et agents contenant ceux-ci
WO2009077471A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009077443A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009077500A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009098232A1 (fr) 2008-02-05 2009-08-13 Basf Se Microcapsules comprenant un tensioactif lipophile et une huile
WO2010029003A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés triazoles, leur utilisation et agents les contenant
WO2010029002A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés de triazole, leur utilisation ainsi qu'agents les contenant
WO2010029000A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés de triazole, leur utilisation ainsi qu'agents les contenant
WO2010029001A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés triazoles, leur utilisation et agents les contenant
WO2010031847A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010031721A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010031842A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010031848A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010040718A1 (fr) 2008-10-07 2010-04-15 Basf Se Composés triazole et imidazole, leur utilisation et agents les contenant
WO2010064266A1 (fr) 2008-12-03 2010-06-10 Lamberti S.P.A. Composition liquide pour concentrés pesticides

Patent Citations (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577515A (en) 1963-12-13 1971-05-04 Pennwalt Corp Encapsulation by interfacial polycondensation
US3516941A (en) 1966-07-25 1970-06-23 Minnesota Mining & Mfg Microcapsules and process of making
US4087376A (en) 1974-07-10 1978-05-02 Ncr Corporation Capsule manufacture
US4280833A (en) 1979-03-26 1981-07-28 Monsanto Company Encapsulation by interfacial polycondensation, and aqueous herbicidal composition containing microcapsules produced thereby
US4414210A (en) 1979-10-02 1983-11-08 Rohm And Haas Company 2-Hydroxyarylethyltriazole fungicides
DE3337937A1 (de) 1982-10-28 1984-05-03 Sandoz-Patent-GmbH, 7850 Lörrach Neue azolderivate
DE3315681A1 (de) 1983-04-29 1984-10-31 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von oxiranen
EP0451878A1 (fr) 1985-01-18 1991-10-16 Plant Genetic Systems, N.V. Modification de plantes par techniques de génie génétique pour combattre ou contrôler les insectes
DE3601927A1 (de) 1986-01-23 1987-07-30 Basf Ag Alpha, beta-substituierte acroleine, verfahren zu deren herstellung und deren verwendung
US5229122A (en) 1986-02-07 1993-07-20 Burroughs Wellcome Co. Pesticidal compositions
EP0374753A2 (fr) 1988-12-19 1990-06-27 American Cyanamid Company Toxines insecticides, gènes les codant, anticorps les liant, ainsi que cellules végétales et plantes transgéniques exprimant ces toxines
EP0378953A1 (fr) 1988-12-29 1990-07-25 Rhone-Poulenc Agrochimie Benzylidène azolylméthylecycloalcane et utilisation comme fongicide
US5049182A (en) 1989-02-03 1991-09-17 Ici Americas Inc. Single-package agricultural formulations combining immediate and time-delayed delivery
EP0386557A1 (fr) 1989-03-10 1990-09-12 BASF Aktiengesellschaft Méthode pour combattre les champignons excluant le cas du traitement du corps humain ou animal.
EP0392225A2 (fr) 1989-03-24 1990-10-17 Ciba-Geigy Ag Plantes transgéniques résistantes aux maladies
EP0421125A2 (fr) 1989-09-09 1991-04-10 BASF Aktiengesellschaft Azolméthyloxirannes fongicides
EP0427529A1 (fr) 1989-11-07 1991-05-15 Pioneer Hi-Bred International, Inc. Lectines larvicides, et résistance induite des plantes aux insectes
EP0457154A1 (fr) 1990-05-16 1991-11-21 BASF Aktiengesellschaft Microcapsules
DE4030039A1 (de) 1990-09-22 1992-03-26 Bayer Ag Verfahren zur herstellung von 2-(1-chlor-cyclopropyl)-1- (2-chlor-phenyl)-3-(1,2,4-triazol-1-yl- propan-2-ol
WO1993007278A1 (fr) 1991-10-04 1993-04-15 Ciba-Geigy Ag Sequence d'adn synthetique ayant une action insecticide accrue dans le mais
US5310721A (en) 1992-01-03 1994-05-10 Ciba-Geigy Corporation Process for the preparation of microcapsules using a salt of a partial ester of a styrene-maleic anhydride copolymer
EP0619073A2 (fr) 1993-04-05 1994-10-12 Monsanto Company Formulations fluides pesticides à base d'eau
EP0655443A2 (fr) 1993-11-11 1995-05-31 Kureha Chemical Industry Co., Ltd. Procédé pour la préparation de dérivées à azolylméthyl cycloalcanol
WO1995013698A1 (fr) 1993-11-15 1995-05-26 Zeneca Limited Microcapsules contenant des suspensions de composes biologiquement actifs
WO1995034656A1 (fr) 1994-06-10 1995-12-21 Ciba-Geigy Ag Nouveaux genes du bacillus thuringiensis codant pour des toxines actives contre les lepidopteres
WO1996003040A1 (fr) 1994-07-22 1996-02-08 Ciba-Geigy Ag Procede de preparation de microparticules spheriques contenant des composes biologiquement actifs
WO1996016048A1 (fr) 1994-11-21 1996-05-30 Bayer Aktiengesellschaft Derives triazolyle microbicides
WO1996038440A1 (fr) 1995-06-01 1996-12-05 Bayer Aktiengesellschaft Triazolylmethyl-oxirannes
WO1996038423A1 (fr) 1995-06-01 1996-12-05 Bayer Aktiengesellschaft (mercapto-triazolylmethyle)-cyclopentanols utilises comme microbicides
US5705174A (en) 1995-06-07 1998-01-06 American Cyanamid Company Process for the preparation of microcapsule compositions
US5910314A (en) 1995-06-07 1999-06-08 American Cyanamid Company Process for the preparation of microcapsule compositions
WO1996041804A1 (fr) 1995-06-13 1996-12-27 Bayer Aktiengesellschaft (mercapto-triazolylmethyl)-dioxacycloalcanes microbicides
DE19528300A1 (de) 1995-08-02 1997-02-06 Bayer Ag 2-Phenylethyl-mercapto-triazole
DE19529089A1 (de) 1995-08-08 1997-02-13 Bayer Ag Mercapto-triazolyl-nitrile
WO1997041107A1 (fr) 1996-04-30 1997-11-06 Bayer Aktiengesellschaft Triazolyl-mercaptides et leur utilisation comme microbicides
EP0917829A1 (fr) 1997-11-12 1999-05-26 Fabriques De Tabac Reunies S.A. Procédé d'acheminement d'un flux de tabac, distributeur et machine de fabrication de cigarettes équipée d'un tel distributeur
EP0917822A1 (fr) 1997-11-20 1999-05-26 Sumitomo Chemical Company, Limited Méthode pour la lutte contre les ectoparasites d'animaux
EP0917828A2 (fr) 1997-11-20 1999-05-26 British-American Tobacco (Germany) GmbH Procédé et dispositif de régulation de l'humidité de sortie du tabac
WO1999044331A1 (fr) 1998-02-27 1999-09-02 Intel Corporation Procede et appareil pour cacher des cles cryptographiques utilisant un codage et un calcul par synchronisation d'autocorrelation
WO2000010392A1 (fr) 1998-08-18 2000-03-02 Fmc Corporation Combinaison d'au moins deux principes actifs au moyen de formulations microencapsulees
EP1109450A1 (fr) 1998-09-05 2001-06-27 Bayer Ag Formulations de microcapsules
WO2000048465A1 (fr) 1999-02-19 2000-08-24 Thies Technology Lutte contre les ravageurs
WO2001067860A1 (fr) 2000-03-13 2001-09-20 Basf Aktiengesellschaft Formulation agrotechnique
US20030119675A1 (en) 2000-03-17 2003-06-26 Hilmar Wolf Microcapsule suspensions
WO2001068234A1 (fr) 2000-03-17 2001-09-20 Bayer Aktiengesellschaft Suspensions en microcapsules
WO2002015701A2 (fr) 2000-08-25 2002-02-28 Syngenta Participations Ag Nouvelles toxines insecticides derivees de proteines cristallines insecticides de $i(bacillus thuringiensis)
WO2003018810A2 (fr) 2001-08-31 2003-03-06 Syngenta Participations Ag Toxines cry3a modifiees et sequences d'acides nucleiques les codant
WO2003037084A1 (fr) 2001-10-31 2003-05-08 Syngenta Limited Formulations pesticides
WO2003052073A2 (fr) 2001-12-17 2003-06-26 Syngenta Participations Ag Nouvel evenement du mais
WO2003099005A1 (fr) 2002-05-29 2003-12-04 Bayer Cropscience Ag Formulations pour microcapsules
WO2004017734A1 (fr) 2002-08-22 2004-03-04 Syngenta Limited Composition agrochimique microencapsulee
WO2005036963A1 (fr) 2003-09-23 2005-04-28 Bayer Cropscience Aktiengesellschaft Suspensions concentrees
WO2005056548A1 (fr) 2003-12-11 2005-06-23 Cheminova A/S Epoxiconazole enantiomeriquement pur et ses utilisations en tant qu'agent phytosanitaire
WO2008071649A2 (fr) 2006-12-13 2008-06-19 Basf Se Microcapsules
DE102007055813A1 (de) 2006-12-22 2008-06-26 Basf Se Thermisch zerstörbare Mikrokapseln
WO2009077497A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, utilisation de ceux-ci et agents contenant ceux-ci
WO2009077471A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009077443A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009077500A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009098232A1 (fr) 2008-02-05 2009-08-13 Basf Se Microcapsules comprenant un tensioactif lipophile et une huile
WO2010029003A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés triazoles, leur utilisation et agents les contenant
WO2010029002A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés de triazole, leur utilisation ainsi qu'agents les contenant
WO2010029000A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés de triazole, leur utilisation ainsi qu'agents les contenant
WO2010029001A1 (fr) 2008-09-09 2010-03-18 Basf Se Composés triazoles, leur utilisation et agents les contenant
WO2010031847A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010031721A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010031842A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010031848A1 (fr) 2008-09-22 2010-03-25 Basf Se Composés d'imidazole et de triazole, leur utilisation et agents les contenant
WO2010040718A1 (fr) 2008-10-07 2010-04-15 Basf Se Composés triazole et imidazole, leur utilisation et agents les contenant
WO2010064266A1 (fr) 2008-12-03 2010-06-10 Lamberti S.P.A. Composition liquide pour concentrés pesticides

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"The Pesticide Manual", 2006, BRITISH CROP PROTECTION COUNCIL
AUSTRAL. J. AGRICULT. RES., vol. 58, 2007, pages 708
PEST MANAGEM. SCI., vol. 61, 2005, pages 246
PEST MANAGEM. SCI., vol. 61, 2005, pages 258
PEST MANAGEM. SCI., vol. 61, 2005, pages 269
PEST MANAGEM. SCI., vol. 61, 2005, pages 277
PEST MANAGEM. SCI., vol. 61, 2005, pages 286
PEST MANAGEM. SCI., vol. 64, 2008, pages 326
PEST MANAGEM. SCI., vol. 64, 2008, pages 332
PESTIC. SCI, vol. 11, 1980, pages 95
RESEARCH DISCLOSURE, vol. 297, 1989, pages 13
SCIENCE, vol. 316, 2007, pages 1185
WEED SCI., vol. 57, 2009, pages 108

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10271547B2 (en) * 2015-02-18 2019-04-30 Melchior Material And Life Science France Particles containing pheromones and production process
WO2017023819A1 (fr) * 2015-07-31 2017-02-09 Summit Agro Usa, Llc Concentré en suspension

Also Published As

Publication number Publication date
AR085757A1 (es) 2013-10-23

Similar Documents

Publication Publication Date Title
DK2731935T3 (en) FUNGICIDE SUBSTITUTED 2- [2-HALOGENALKYL-4- (PHENOXY) -PHENYL] -1- [1,2,4] TRIAZOL-1-YLETHANOL COMPOUNDS
EP2934147B1 (fr) Compositions comprenant un composé triazole
JP2014520828A (ja) 殺菌性アルキル−置換２−［２−クロロ−４−（４−クロロ−フェノキシ）−フェニル］−１−［１，２，４］トリアゾール−１−イル−エタノール化合物
US20130130898A1 (en) Fungicidal Compositions
EP3154949B1 (fr) Composés [1,2,4]-triazoles et imidazoles substitués utilisés comme fongicides
JP2014520833A (ja) 殺菌性フェニルアルキル−置換２−［２−クロロ−４−（４−クロロ−フェノキシ）−フェニル］−１−［１，２，４］トリアゾール−１−イル−エタノール化合物
MX2014000824A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-alcoxi-3-metil-butil}-1h-[1,2,4]triazol sustituidos.
EP2815649A1 (fr) Mélanges fongicides II comprenant des fongicides de type strobilurine
MX2014000511A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-etoxi-etil}-1h-[1,2,4]triazol sustituidos.
US20120322654A1 (en) Synergistic fungicidal mixtures
JP2014525404A (ja) 殺菌性置換１−｛２−［２−ハロ−４−（４−ハロゲン−フェノキシ）−フェニル］−２−アルキニルオキシ−エチル｝−１ｈ−［１，２，４］トリアゾール化合物
CN103649058A (zh) 杀真菌的烷基-和芳基取代的2-[2-氯-4-(二卤代苯氧基)苯基]-1-[1,2,4]三唑-1-基乙醇化合物
WO2014029697A1 (fr) Mélanges ternaires fongicides comprenant du fluaziname
JP2014524431A (ja) 殺菌性置換１−｛２−［２−ハロ−４−（４−ハロゲン−フェノキシ）−フェニル］−２−アルコキシ−ヘキシル｝−１ｈ−［１，２，４］トリアゾール化合物
MX2013013239A (es) Mezclas fungicidas sinergicas que comprenden 2,3,5,6-tetraciano-[1 ,4]ditiina.
CN104427872A (zh) 取代的噻二唑类及其作为杀真菌剂的用途
EP2839745A1 (fr) Formulations agrochimiques comprenant un 2-éthyl-hexanol alkoxylat
EP2560492B1 (fr) Mélanges fongicides comprénant d'amétoctradine et un dérivé de tétrazolyloxime
EP2751085B1 (fr) Cocristaux de cyprodinil et de dithianon
EP2481284A2 (fr) Mélanges de pesticides
WO2011117271A2 (fr) Mélanges fongicides basés sur des azolopyrimidinylamines
JP2014513081A (ja) 植物病原性菌類を駆除するための置換されたジチイン−ジカルボキシイミドの使用
WO2012130823A1 (fr) Concentrés en suspension
JP2014516356A (ja) 植物病原性菌類を駆除するための置換されたジチイン−テトラカルボキシイミドの使用
NZ619900B2 (en) Fungicidal alkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12713026

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12713026

Country of ref document: EP

Kind code of ref document: A1